<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Commun</journal-id><journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id><journal-title-group><journal-title>Nature Communications</journal-title></journal-title-group><issn pub-type="epub">2041-1723</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39198433</article-id><article-id pub-id-type="pmc">PMC11358264</article-id>
<article-id pub-id-type="publisher-id">51634</article-id><article-id pub-id-type="doi">10.1038/s41467-024-51634-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>IGF2BP3 promotes mRNA degradation through internal m<sup>7</sup>G modification</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Chang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Dou</surname><given-names>Xiaoyang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Yutao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1872-9978</contrib-id><name><surname>Zhang</surname><given-names>Lisheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8578-1568</contrib-id><name><surname>Dai</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2498-9963</contrib-id><name><surname>Liu</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9968-9909</contrib-id><name><surname>Wu</surname><given-names>Tong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4319-7424</contrib-id><name><surname>He</surname><given-names>Chuan</given-names></name><address><email>chuanhe@uchicago.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024mw5h28</institution-id><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>Department of Chemistry, Department of Biochemistry and Molecular Biology, and Institute for Biophysical Dynamics, </institution><institution>The University of Chicago, </institution></institution-wrap>Chicago, IL 60637 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024mw5h28</institution-id><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>Howard Hughes Medical Institute, </institution><institution>The University of Chicago, </institution></institution-wrap>Chicago, IL 60637 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02v51f717</institution-id><institution-id institution-id-type="GRID">grid.11135.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2256 9319</institution-id><institution>State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, </institution><institution>Peking University, </institution></institution-wrap>Beijing, 100871 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02v51f717</institution-id><institution-id institution-id-type="GRID">grid.11135.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2256 9319</institution-id><institution>Beijing Advanced Center of RNA Biology (BEACON), </institution><institution>Peking University, </institution></institution-wrap>Beijing, 100871 China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Present Address: Department of Genetics, School of Medicine, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q4vv597</institution-id><institution-id institution-id-type="GRID">grid.24515.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1450</institution-id><institution>Present Address: Division of Life Science, </institution><institution>The Hong Kong University of Science and Technology, </institution></institution-wrap>Hong Kong, China </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q4vv597</institution-id><institution-id institution-id-type="GRID">grid.24515.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1450</institution-id><institution>Present Address: Department of Chemistry, </institution><institution>The Hong Kong University of Science and Technology, </institution></institution-wrap>Hong Kong, China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><elocation-id>7421</elocation-id><history><date date-type="received"><day>24</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024, corrected publication 2025</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par2">Recent studies have suggested that mRNA internal m<sup>7</sup>G and its writer protein METTL1 are closely related to cell metabolism and cancer regulation. Here, we identify that IGF2BP family proteins IGF2BP1-3 can preferentially bind internal mRNA m<sup>7</sup>G. Such interactions, especially IGF2BP3 with m<sup>7</sup>G, could promote the degradation of m<sup>7</sup>G target transcripts in cancer cells. IGF2BP3 is more responsive to changes of m<sup>7</sup>G modification, while IGF2BP1 prefers m<sup>6</sup>A to stabilize the bound transcripts. We also demonstrate that p53 transcript, <italic>TP53</italic>, is m<sup>7</sup>G-modified at its 3&#x02019;UTR in cancer cells. In glioblastoma, the methylation level and the half lifetime of the modified transcript could be modulated by tuning IGF2BP3, or by site-specific targeting of m<sup>7</sup>G through a dCas13b-guided system, resulting in modulation of cancer progression and chemosensitivity.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par3">Here the authors show that the binding of IGF2BP1-3, especially IGF2BP3, with m<sup>7</sup>G, could promote the degradation of m<sup>7</sup>G target transcripts in cancer cells. In glioblastoma, tuning the m<sup>7</sup>G level of TP53 results in modulation of cancer progression and chemosensitivity.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>RNA metabolism</kwd><kwd>RNA modification</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000051</institution-id><institution>U.S. Department of Health &#x00026; Human Services | NIH | National Human Genome Research Institute (NHGRI)</institution></institution-wrap></funding-source><award-id>R01 HL155909</award-id><principal-award-recipient><name><surname>He</surname><given-names>Chuan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par4">To date, over 150 modifications have been identified on cellular RNA, many of which are known to exist in eukaryotes<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Among them, <italic>N</italic><sup>6</sup>-methyladenosine (m<sup>6</sup>A), discovered in eukaryotic mRNA in 1974, is the most prevalent internal modification in mRNA and long non-coding RNA (lncRNA)<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. The modulators of RNA modifications can be cataloged into three groups: writers, erasers, and readers, which install, remove, and recognize the modifications. This new layer of regulation impacts many regulatory processes. For example, the m<sup>6</sup>A writer METTL3 has been related to both transcriptional and post-transcription regulations<sup><xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup>. The depletion of erasers ALKBH5 or FTO notably impacts both nuclear and cytosolic regulations of mRNA processing and metabolism<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup>. Various m<sup>6</sup>A-binding proteins bind the modification and modulate cellular localization, stability, and translation of the target transcripts. The interaction of m<sup>6</sup>A with its reader YTHDF2 destabilizes modified mRNAs while its interaction with YTHDF1 could affect translation<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par5">The dysregulation of RNA modifications or their regulators has been associated with human diseases including cancer. For example, demethylase FTO has been reported to be upregulated in <italic>MLL</italic>-rearranged AML, which promotes cell viability and leukemogenesis through the demethylation of functionally important genes<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. In glioblastoma, the overexpression of m<sup>6</sup>A methyltransferase METTL3 or METTL14, or correspondingly, the knockdown of <italic>FTO</italic> inhibited the growth and self-renewal of glioblastoma stem cells<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. The m<sup>6</sup>A reader IGF2BP2 was reported to interact with the methylation on lncRNA <italic>DANCR</italic> to stabilize the transcript, thus promoting cell growth in pancreatic cancer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par6">Apart from the well-known m<sup>6</sup>A, other mRNA modifications have also been identified and mapped within the transcriptome, such as internal <italic>N</italic><sup>7</sup>-methylguanosine (m<sup>7</sup>G). m<sup>7</sup>G, an ubiquitous mRNA cap modification critical to mRNA life cycle<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref></sup>, also exists as an internal modification within transfer RNA (tRNA)<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and ribosomal RNA (rRNA)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. However, it was not until recently that internal m<sup>7</sup>G on mRNA has been identified and mapped in cancer cells<sup><xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref></sup>. The methyltransferase complex of tRNA m<sup>7</sup>G modification (METTL1-WDR4) was found to be responsible for a subset of mRNA internal m<sup>7</sup>G installation<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. METTL1 has long been highlighted among the methyltransferase-like protein family as its high expression is notably associated with the high-grade tumors and poor prognosis<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. Specifically, the high expression of METTL1, as the tRNA methyltransferase, could impact translation in glioblastoma and neuroblastoma through modulating levels of&#x000a0;m<sup>7</sup>G-modified tRNAs<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>. A recent study identified QKI family proteins as the readers of internal m<sup>7</sup>G modification<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. QKI proteins, especially QKI7, could shuttle m<sup>7</sup>G transcripts into stress granules under stress conditions and further impact decay and translation of these transcripts. These studies have suggested that internal m<sup>7</sup>G, together with its methyltransferase METTL1 and potential readers, is closely related to mRNA metabolism and cellular regulation processes such as cancer development.</p><p id="Par7">Here, we present the IGF2BP proteins as the protein family that could preferentially bind internal m<sup>7</sup>G over G on mRNA in cancer cells. While IGF2BPs have been identified as m<sup>6</sup>A readers, the individual members display distinct preferences toward mRNA m<sup>6</sup>A and m<sup>7</sup>G modifications. The interaction of m<sup>7</sup>G with IGF2BP1 and IGF2BP3, especially the latter one with higher affinity, could promote the degradation of m<sup>7</sup>G-modified transcripts, whereas IGF2BP1 prefers m<sup>6</sup>A and stabilizes the bound transcripts. We then took advantage of the inactive dCas13b tethering system to specifically target individual m<sup>7</sup>G sites. The tethering of either IGF2BP3 or the methyltransferase catalytic core METTL1 would decrease the half lifetime of the target transcripts. We found that IGF2BP3 could promote the degradation of m<sup>7</sup>G target transcripts through its interaction with EXOSC2 of the exosome complex. Inspired by the high correlation of METTL1 with p53 related pathways in glioma, we mined and found that the p53 transcript, <italic>TP53</italic>, is m<sup>7</sup>G-modified at its 3&#x02019;UTR by METTL1. We further tested in selected glioblastoma cells and demonstrated that the application of dCas13b tethering systems (IGF2BP3 or METTL1) on <italic>TP53</italic> could promote its decay and downregulate both the transcript and protein levels, which notably impact glioblastoma progression and chemotherapy resistance.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>METTL1 is involved in glioma and p53-related pathways and <italic>TP53</italic> methylation</title><p id="Par8">METTL1 is highly expressed in various tumors compared to normal tissues (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1a</xref>). It has been reported to play important roles in tumorigenesis or stemness maintenance<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref></sup>. A recent study showed that the upregulation of METTL1, as tRNA methyltransferase, could stabilize the m<sup>7</sup>G-modified tRNA and promote translation of oncogenic transcripts in neuroblastoma<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Immunohistochemical staining (IHC) data in other studies also demonstrated high protein expression levels of METTL1 in primary glioblastoma tissue compared to normal cerebral tissue<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Through mining TCGA datasets, we also noticed that, in glioma, the higher expression level of METTL1 is closely correlated to poorer survival rate (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). However, such effect of METTL1 expression on the survival rate was dramatically diminished in patients with <italic>TP53</italic> mutations (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1b</xref>). We observed that METTL1 is highly involved in p53-related pathways including cell cycle and p53 signaling (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). In addition, the tumor survival dependence of WDR4, the METTL1 methyltransferase partner, is not only significantly correlated with that of METTL1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>), but also shows close relationship with these pathways (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1c</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>METTL1 may regulate <italic>TP53</italic> abundance through its 3&#x02019;UTR m<sup>7</sup>G methylation in cancer cells.</title><p><bold>a</bold>, <bold>b</bold> Kaplan-Meier survival analysis in TCGA database for Glioma (TCGA-GBMLGG): the entire dataset (<bold>a</bold>), and cases with mutant <italic>TP53</italic> (<bold>b</bold>). The patients were divided into two groups of equal size based on the <italic>METTL1</italic> levels. The ones lower than the median value are all grouped into the &#x0201c;Low&#x0201d; group while the ones higher than the median value are all grouped into &#x0201c;High&#x0201d;. <italic>P</italic>-value detected by log-rank test. <bold>c</bold> Gene Set Enrichment Analysis (GSEA) of genes in &#x02018;cell cycle&#x02019; and &#x02018;p53 signaling pathway&#x02019; KEGG pathways against ranked list of genes according to <italic>METTL1</italic> expression level. <bold>d</bold> The correlation of CERES dependency score between <italic>METTL1</italic> and <italic>WDR4</italic>, with standard error marked in gray. The CERES was developed to estimate gene-dependency level from CRISPR-Cas9 essentiality screens while accounting for the effects<sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. <bold>e</bold> The integrative genomics viewer (IGV) plots showing the m<sup>7</sup>G-MeRIP-seq peaks at the 3&#x02019; UTR end of <italic>TP53</italic>, which also overlap with METTL1 and WDR4 PAR-CLIP peaks. A minor m<sup>6</sup>A peak was detected in the distant CDS region adjacent to 5&#x02019;UTR region. Y-axis showing counts per ten million reads. <bold>f</bold> IGV plots showing the m<sup>7</sup>G-MeRIP-seq peaks at the 3&#x02019; UTR end of <italic>TP53</italic> upon stable knockdown of <italic>METTL1</italic> compared to control in HepG2 (GSE112276). Y-axis showing counts per ten million reads. <bold>g</bold> Relative m<sup>7</sup>G methylation levels of the <italic>TP53</italic> 3&#x02019; UTR locus upon <italic>METTL1</italic> knockdown in HepG2 cells, normalized to the methylation level in the knockdown control cells. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>h</bold> Relative m<sup>6</sup>A (gray) and m<sup>7</sup>G (blue) methylation levels of the 3&#x02019; UTR region of <italic>TP53</italic> based on MeRIP enrichment followed by qPCR quantification. Mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. <bold>i</bold> The mRNA levels of <italic>TP53</italic> in different cell lines. For each cell, the <italic>TP53</italic> expression level was normalized to total RNA amount respectively. And the comparison across the cell lines were normalized to U87MG. Mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. <bold>j</bold> Spearman correlation of the 3&#x02019; UTR m<sup>7</sup>G methylation level and the mRNA abundance of <italic>TP53</italic>. Significance was determined by two-sided Pearson&#x02019;s correlation test. All source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2024_51634_Fig1_HTML" id="d33e695"/></fig></p><p id="Par9"><italic>TP53</italic>, one of the most frequently mutated gene in human cancer, is well known as the guardian of the genome<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. We were curious how METTL1 expression correlates with glioma survival in a <italic>TP53</italic>-mutation dependent way, and whether METTL1 and WDR4, also as the writer for a subset of internal mRNA m<sup>7</sup>G modification, could affect tumor pathways through mRNA regulation. We therefore examined the methylation levels of the transcripts related to the p53 pathways based on the published m<sup>7</sup>G-MeRIP-seq datasets in HepG2 cells. Interestingly, we found that the transcript of p53, <italic>TP53</italic>, is m<sup>7</sup>G-methylated in its 3&#x02019; UTR, and the methylation peak overlaps well with the binding sites of METTL1 and WDR4 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>). The methylation level also decreased upon <italic>METTL1</italic> stable&#x000a0;knockdown (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1f</xref>), which is reproducible upon the transient knockdown of <italic>METTL1</italic> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1g</xref>), suggesting that METTL1 is involved in the m<sup>7</sup>G methylation at the 3&#x02019; UTR of <italic>TP53</italic>.</p><p id="Par10">As p53 is frequently mutated in glioblastoma<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and the effect of METTL1 expression on the survival rate of glioma/glioblastoma could be dramatically affected by p53 mutation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1b</xref>), we selected several representative glioblastoma cell lines with different <italic>TP53</italic> status to study the effects of m<sup>7</sup>G methylation on <italic>TP53</italic> transcript<sup><xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref></sup>: U87MG and A172 express wildtype p53. LN229 has a P98L mutation in the proline-rich domain<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, which was reported to remain a partial wild-type function<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. T98G cells express a p53 mutant protein with M237I mutation that severely compromises the transactivation capacity of the wild-type protein<sup><xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref></sup>. It has also been reported that cells expressing the M237I-p53 mutant have a lower chemosensitivity to temozolomide (TMZ) treatment compared to the wild-type<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. We first quantified the relative m<sup>6</sup>A or m<sup>7</sup>G modification levels of the entire <italic>TP53</italic> transcript using MeRIP enrichment followed by qPCR quantification and observed little difference (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1d</xref>). However, when we examined the methylation level at the 3&#x02019; UTR, we noticed huge variations across different cell lines. While no m<sup>6</sup>A enrichment was observed for all cell lines, LN229 and U87MG presented the highest m<sup>7</sup>G modification levels, and the other two cell lines had low m<sup>7</sup>G when compared to HepG2 cells we used as the reference (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1h</xref>). We also noticed that the mRNA level of <italic>TP53</italic> varied quite notably across different cell lines (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1i</xref>), so as its protein expression levels (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1e</xref>), and surprisingly, the m<sup>7</sup>G methylation level at the 3&#x02019; UTR displayed a negative correlation with the <italic>TP53</italic> transcript abundance (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1j</xref>). We didn&#x02019;t observe much correlation of the protein levels of m<sup>7</sup>G regulators (METTL1, WDR4) with the <italic>TP53</italic> transcript level, as these proteins remain similar in the expression levels across tested cell lines (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1e</xref>). We proceeded to ask whether there are potential m<sup>7</sup>G binding proteins that may explain the observed negative correlation between the internal m<sup>7</sup>G level on the target mRNA and the transcript abundance.</p></sec><sec id="Sec4"><title>IGF2BP family proteins identified as the readers of internal m<sup>7</sup>G modification</title><p id="Par11">We started with pulling down potential binding proteins of mRNA internal m<sup>7</sup>G in HepG2 cells. As m<sup>7</sup>G is not compatible with oligo synthesizer, we designed a probe with only one G in the DNA template and prepared RNA probes using either unmodified GTP or m<sup>7</sup>GTP during in vitro transcription. The probes were then biotinylated at the 3&#x02019; end and incubated with cell lysate to pull down interactive proteins, followed by protein mass spectrometry identification (data available via ProteomeXchange with identifier PXD049390, proteins enriched by m<sup>7</sup>G probes listed in Supplementary Data&#x000a0;<xref rid="MOESM4" ref-type="media">1</xref>). Our results highlighted IGF2BP family proteins as the ones showing preference to internal m<sup>7</sup>G over G in RNA (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). The recently reported reader QKI<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> was also observed.<fig id="Fig2"><label>Fig. 2</label><caption><title>IGF2BP family proteins bind to mRNA internal m<sup>7</sup>G.</title><p><bold>a</bold> Protein mass spectrometry results with x-axis showing general binding on unmodified RNA and y-axis showing the binding of m<sup>7</sup>G over G. To calculate enrichment ratios for proteins identified by only one probe, 0.001 was added to all normalized spectral abundance factor (NSAF). The IGF2BP family proteins are highlighted in red. The reported reader QKI is marked in green. Top-ranked proteins are listed in Supplementary Data 1. <bold>b</bold> Western blot of HepG2 cell lysate in vitro pulldown using the m<sup>7</sup>G probe and G probe, respectively, with the estimation of enrichment folds plotted on the right. This experiment was repeated independently twice with similar results. The probe sequence is listed below the blots. <bold>c</bold> LC-MS/MS quantification of m<sup>7</sup>G/G levels showing enrichment of m<sup>7</sup>G after immunoprecipitation using antibodies against IGF2BPs. Mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. <bold>d</bold> Venn diagram of overlaps of transcripts that were bound by IGF2BPs and modified with m<sup>7</sup>G. <bold>e</bold> Left: metagene plot of IGF2BPs binding sites (not overlapped with m<sup>7</sup>G modified sites) (orange), m<sup>7</sup>G modified sites (not overlapped with IGF2BPs binding sites) (blue) and their overlapping sites (green). Right: Lollipop plot showing the overlaps between m<sup>7</sup>G and IGF2BPs quantified using Jaccard Index. <bold>f</bold> Venn diagram of overlaps of peaks that were bound by IGF2BPs and modified with m<sup>7</sup>G. <bold>g</bold> Proportion of m<sup>7</sup>G sites overlapping with IGF2BPs binding sites. m<sup>7</sup>G sites were categorized into groups based on m<sup>7</sup>G enrichment quantified as log<sub>2</sub>FC(IP/Input). <bold>h</bold> Enrichment of m<sup>6</sup>A (left) and m<sup>7</sup>G (right) with IGF2BP1, IGF2BP2, and IGF2BP3 motifs, respectively, quantified with odds ratio. <bold>i</bold> Binding intensity of IGF2BP1, IGF2BP2, and IGF2BP3 at m<sup>7</sup>G sites and their flanking 500&#x02009;bp, respectively. All source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2024_51634_Fig2_HTML" id="d33e938"/></fig></p><p id="Par12">IGF2BPs are important RNA binding proteins actively involved in RNA metabolism and diseases<sup><xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref></sup>. Previous studies have identified IGF2BPs as m<sup>6</sup>A readers to stabilize m<sup>6</sup>A transcripts and regulate translation<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. To validate our mass spectrometry results, we performed western blot to verify the binding affinity of IGF2BPs on m<sup>7</sup>G (vs. G) probes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b) and m</xref><sup>6</sup>A (vs. A) probes in parallel (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2a</xref>). Though similar in protein structural arrangements, the three members differed slightly in the binding affinity of different modifications. IGF2BP1 appears to prefer m<sup>6</sup>A, while m<sup>7</sup>G was more favored by IGF2BP2 and IGF2BP3. The m<sup>7</sup>G probes were also more favorably bound by these proteins compared to the G-bearing probes in the electrophoresis mobility shift assay (EMSA) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2b</xref>). We further quantified the internal m<sup>7</sup>G/G levels of RNA bound by IGF2BP proteins through in vitro pulldown in HepG2 cell lysate using corresponding antibodies and compared those to that of the input. The m<sup>7</sup>G modification levels were roughly doubled in all three IGF2BP protein-bound fractions (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). Such results remained similar when we overexpressed METTL1 in HepG2 cells; overexpressed cells showed higher internal m<sup>7</sup>G/G levels upon all three IGF2BP pulldown, suggesting that IGF2BP family members could all recognize METTL1 target transcripts (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2c</xref>). Altogether, our results suggest preferential binding of RNA internal m<sup>7</sup>G by IGF2BP proteins.</p><p id="Par13">The structures of IGF2BPs have been well studied. They share a characteristic arrangement of six canonical RNA binding domains, namely two consecutive RNA recognition motifs (RRMs) followed by four hnRNP K homology (KH) domains, where RRM1-2, KH1-2, and KH3-4 are arranged into pairs<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. Previous studies have shown that the KH3-4 domains are&#x000a0;critical for IGF2BPs binding to m<sup>6</sup>A: mutated KH3-4 domains abolished the binding of all three proteins with m<sup>6</sup>A<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. To evaluate IGF2BPs&#x02019; binding of internal m<sup>7</sup>G, we overexpressed FLAG-tagged IGF2BP mutants with truncated RRM domains or mutated KH domains and tested their binding towards m<sup>7</sup>G probes (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2d</xref>). The KH mutations refer to the full-length protein with mutations of GxxG to GEEG in the KH domains as previously described<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The cell lysate was incubated with m<sup>7</sup>G-modified biotinylated probes, and the binding intensity was examined by pulldown and western blot, and further quantified with comparison to the enrichment levels in the wild-type cell lysate. The mutation on KH3-4 domains almost abolished the binding affinity, suggesting that KH3-4 domains are critical to the modification binding, while the RRM domain did not contribute much. A slight difference occurred in the case of IGF2BP3. When KH3-4 domains of IGF2BP3 were mutated, this protein still displayed a slight binding towards the m<sup>7</sup>G modification, implying that the KH1-2 domains might also assist the m<sup>7</sup>G binding in IGF2BP3. In correspondence to the variations in binding affinities toward m<sup>6</sup>A over A or m<sup>7</sup>G over G (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">2a</xref>), our studies of different binding domains suggested that IGF2BPs might bind m<sup>6</sup>A and m<sup>7</sup>G in a similar but not identical way. The structural and most likely electrostatic differences of these two modified bases might explain these variations, which await further structural investigations of the bound protein complexes.</p></sec><sec id="Sec5"><title>Transcriptomic binding of IGF2BP family proteins on internal m<sup>7</sup>G modification</title><p id="Par14">To better understand the binding between m<sup>7</sup>G and IGF2BPs and potential impacts at the transcriptome level, we performed photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) of the three IGF2BPs in HepG2 cells and overlapped their binding sites with m<sup>7</sup>G-MeRIP-seq, and in parallel with m<sup>6</sup>A-MeRIP-seq as a reference. Consistent to the previous report<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, over two-thirds of IGF2BPs-bound mRNAs were m<sup>6</sup>A-modified (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3a</xref>). More than half of the IGF2BPs targets are modified by internal m<sup>7</sup>G (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2d</xref>), comparably among all three members (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3b</xref>).</p><p id="Par15">IGF2BPs are regulators mainly bound at the 3&#x02019; UTR of its target transcripts (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). The metagene profiles confirmed overlap of the m<sup>7</sup>G peaks with IGF2BP-bound sites (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref> left in green), with most overlapping sites at the 3&#x02019; UTR compared to the non-overlapped but methylated ones (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref> left in blue), similar to the case of m<sup>6</sup>A modification (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3c</xref>). Such patterns are conserved across three IGF2BP members (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3d</xref> and <xref rid="MOESM1" ref-type="media">3e</xref>). When examining their binding overlaps at the 3&#x02019; UTR we observed about 10% of the IGF2BP binding sites adjacent to m<sup>7</sup>G peaks (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3f</xref>), close to that around the m<sup>6</sup>A peaks (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3g</xref>). Correspondingly, m<sup>7</sup>G sites with higher methylation levels showed better overlap with IGF2BP binding sites (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2g</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3h</xref>).</p><p id="Par16">Structural studies have shown that the KH1-2 and KH3-4 domains of IGF2BPs are prearranged to recognize bipartite RNA sequence motifs, with certain variations among the three members<sup><xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref></sup>. For example, IGF2BP3 has been found to prefer motifs such as GGCA-N<sub>(9-25)</sub>-CA or CGGC-N<sub>(15-25)</sub>-CA<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. We therefore calculated the possibility that an m<sup>6</sup>A or m<sup>7</sup>G peak could cover the consensus favorable motifs of each IGF2BP protein. m<sup>7</sup>G transcripts are particularly favored by IGF2BP3 while m<sup>6</sup>A are more preferred by IGF2BP1 and IGF2BP3 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2h</xref>), further supporting the difference of IGF2BP3 binding on m<sup>7</sup>G versus m<sup>6</sup>A.</p><p id="Par17">In addition to m<sup>7</sup>G-MeRIP-seq, we took advantage of m<sup>7</sup>G-seq at base resolution to study the binding of IGF2BPs. The plots with more quantitative m<sup>7</sup>G-seq dataset also precisely demonstrated that IGF2BPs, especially IGF2BP3, bind at m<sup>7</sup>G sites (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2i</xref>). As a reference, WDR4, the RNA binding partner in the internal m<sup>7</sup>G writer complex, exhibited a similar pattern (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3i</xref>). Altogether, we found that IGF2BPs interacts with internal m<sup>7</sup>G located at 3&#x02019; UTR of mRNA in HepG2 cells.</p></sec><sec id="Sec6"><title>IGF2BP1 and IGF2BP3 promote decay of the m<sup>7</sup>G-modified transcripts</title><p id="Par18">IGF2BPs have been shown to stabilize m<sup>6</sup>A transcripts and play important roles in cancer development and prognosis<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR50">50</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref></sup>. We asked if IGF2BPs could affect the stability of m<sup>7</sup>G-modified transcripts. We performed transient knockdown of the three IGF2BP proteins (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4a</xref>) followed by the RNA lifetime sequencing, with data highly consistent between each pair of replicates (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4b</xref>). m<sup>6</sup>A targets were verified to be destabilized (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4c</xref>). However, when it comes to m<sup>7</sup>G transcripts, the half lifetime increased upon the knockdown of <italic>IGF2BP1</italic> and <italic>IGF2BP3</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). The stabilization effect was positively correlated to the enrichment of both m<sup>7</sup>G modification levels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>) and IGF2BPs binding intensities (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4d</xref>). We further verified the methylation levels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>) within the full-length transcripts of representative genes (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4e</xref>) and confirmed the increased half-lifetime upon <italic>IGF2BP1</italic> and <italic>IGF2BP3</italic> knockdown, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3d</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4f</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>IGF2BP1 and IGF2BP3 promote degradation of m<sup>7</sup>G-modified transcripts with limited interference from m<sup>6</sup>A.</title><p><bold>a</bold> Cumulative curve of gene half lifetime fold-changes (log<sub>2</sub>FC) upon <italic>IGF2BP1</italic> (left), <italic>IGF2BP2</italic> (middle), and <italic>IGF2BP3</italic> (right) knockdown in HepG2. Two independent replicates with two-sided Wilcoxon rank-sum test. Genes were categorized according to whether they were marked with m<sup>7</sup>G or not (non-m<sup>7</sup>G). The box plots on the right side extend from the first to the third quartile (Q1 to Q3), with lines in the middle representing median. Lines extending from both ends of boxes indicate variability outside the range. The minimum and maximum whisker values are calculated as Q1 &#x02212; 1.5&#x02009;*&#x02009;IQR and Q3&#x02009;+&#x02009;1.5&#x02009;*&#x02009;IQR, respectively. <bold>b</bold> Cumulative curve of gene half lifetime fold-changes (log<sub>2</sub>FC) upon <italic>IGF2BP1</italic> (top) and <italic>IGF2BP3</italic> (bottom) knockdown. Two independent replicates with two-sided Wilcoxon rank-sum test. Genes were categorized into four groups according to m<sup>7</sup>G enrichment level (log<sub>2</sub>FC(IP/Input)). <bold>c</bold> Relative m<sup>7</sup>G methylation levels of the transcripts of the selected genes based on m<sup>7</sup>G-MeRIP-qPCR quantification. Mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. <bold>d</bold> Changes in mRNA levels in HepG2 cells with transient knockdown of <italic>IGF2BP1</italic> and <italic>IGF2BP3</italic>. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. Calculated half lifetimes marked in corresponding colors. <bold>e</bold> Pearson correlation between m<sup>7</sup>G levels and m<sup>6</sup>A levels on the transcripts of the same genes. Two-sided <italic>p</italic>-value with standard error marked in gray. <bold>f</bold> Venn diagram of the overlaps of m<sup>6</sup>A peaks, m<sup>7</sup>G peaks, and IGF2BPs PAR-CLIP peaks in 3&#x02019; UTR. <bold>g</bold> Boxplot showing gene half lifetime fold-changes (log<sub>2</sub>FC) upon <italic>IGF2BP3</italic> knockdown. Two independent replicates with two-sided Wilcoxon rank-sum test. Genes were categorized into different groups according to their m<sup>7</sup>G or m<sup>6</sup>A modification level. &#x02018;-&#x02019; represents log<sub>2</sub>FC(IP/Input)&#x02009;&#x0003c;&#x02009;0; &#x02018;+&#x02019; represents log<sub>2</sub>FC(IP/Input)&#x02009;&#x0003e;&#x02009;0 and log<sub>2</sub>FC(IP/Input)&#x02009;&#x0003c;&#x02009;1; &#x02018;++&#x02019; represents log<sub>2</sub>FC(IP/Input)&#x02009;&#x0003e;&#x02009;1. <bold>h</bold> Cumulative curve of gene half lifetime fold-changes (log<sub>2</sub>FC) upon <italic>IGF2BP1</italic> (left), and <italic>IGF2BP3</italic> (right) knockdown. Two independent replicates for each. Genes were categorized into three groups: (1) modified only by m<sup>6</sup>A (non-m<sup>7</sup>G &#x00026; m<sup>6</sup>A), (2) modified only by m<sup>7</sup>G (non-m<sup>6</sup>A &#x00026; m<sup>7</sup>G), and (3) modified by m<sup>7</sup>G and m<sup>6</sup>A (m<sup>7</sup>G &#x00026; m<sup>6</sup>A). The box plots formatted as those in (<bold>3a</bold>). All source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2024_51634_Fig3_HTML" id="d33e1394"/></fig></p><p id="Par19">METTL1-WDR4, the tRNA m<sup>7</sup>G methyltransferase complex, has also been shown to act as mRNA writer for a subset of internal m<sup>7</sup>G modification in cancer cells. To further validate the effects of IGF2BP1 and IGF2BP3 on m<sup>7</sup>G-modified transcripts, we grouped the METTL1 targets according to their methylation changes upon <italic>METTL1</italic> knockdown. The transcripts with more decreases in their m<sup>7</sup>G methylation levels were more responsive to <italic>IGF2BP1</italic> and <italic>IGF2BP3</italic> perturbation, and thus were more stabilized upon knockdown (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4g</xref>). Consistently, the targets of which half lifetime increased more with <italic>METTL1</italic> downregulation were also more stabilized upon <italic>IGF2BP1</italic> and <italic>IGF2BP3</italic> knockdown (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4h</xref>). These results altogether suggest that IGF2BP1 and IGF2BP3 could promote decay of m<sup>7</sup>G-marked transcripts, including the METTL1 targets.</p></sec><sec id="Sec7"><title>m<sup>7</sup>G regulates mRNA stability</title><p id="Par20">Similar as m<sup>6</sup>A (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5a</xref>), m<sup>7</sup>G modifications are generally located at longer exons (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5b</xref>, left), and the modified transcripts, especially those with m<sup>7</sup>G at the 3&#x02019;UTR, are greater in length than unmodified ones (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5b</xref>, right). While m<sup>6</sup>A and m<sup>7</sup>G are similar in distribution when bound by IGF2BPs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">3c</xref>), they acted oppositely in half lifetime regulation (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4c</xref>), which made us wonder about potential crosstalk among these two modifications on the same gene transcript. Unsurprisingly, more than half of the m<sup>7</sup>G-marked transcripts are also modified by m<sup>6</sup>A (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5c</xref>). However, we did not observe a correlation of methylation levels between m<sup>7</sup>G and m<sup>6</sup>A at the transcript level (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3e</xref>). When we examined their potential overlap at the peak level, about 15% of the m<sup>7</sup>G peaks are adjacent to m<sup>6</sup>A peaks (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5d</xref>), and the ratio increased to around 25%, occupying ~15% of the overall m<sup>6</sup>A peaks, in the 3&#x02019; UTRs (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5e</xref>). But when we use IGF2BPs binding sites as reference, the overlapping peaks between both modifications in the 3&#x02019; UTR are limited (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3f</xref>), suggesting little conflict on the regulation of these two modifications through IGF2BPs on the same transcript. We further generated a HepG2 cell line with stable downregulation of <italic>METTL3</italic>, the catalytic component of the m<sup>6</sup>A writer complex, and evaluated RNA half lifetime using RT-qPCR. We observed a consistent stabilization effect on representative target transcripts modified by m<sup>7</sup>G upon <italic>IGF2BP3</italic> knockdown, suggesting that m<sup>7</sup>G targets can be regulated with little impact from m<sup>6</sup>A modification (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5f</xref>).</p><p id="Par21">To distinguish the potential opposite regulation in transcript lifetime by these two modifications, we grouped the target transcripts based on their corresponding m<sup>7</sup>G or m<sup>6</sup>A methylation level, respectively. When comparing m<sup>6</sup>A targets without m<sup>7</sup>G modification to those with high m<sup>7</sup>G modification (from lighter green to darker green in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3g</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5g</xref>), we observed a gradual shift in the half lifetime change from destabilization towards stabilization upon either <italic>IGF2BP1</italic> (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5g</xref>) or <italic>IGF2BP3</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3g</xref>) knockdown. Such patterns are consistent with the different regulatory functions of the two modifications.</p><p id="Par22">To better evaluate the regulation of the IGF2BP proteins on the two modifications, we respectively compared the lifetime changes of their direct targets with either m<sup>6</sup>A or m<sup>7</sup>G, or both modifications (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3h</xref>). The dually modified transcripts showed a similar half lifetime change as those with only m<sup>7</sup>G modification upon <italic>IGF2BP3</italic> knockdown but acted more similarly as m<sup>6</sup>A-only targets upon <italic>IGF2BP1</italic> knockdown, suggesting that IGF2BP3 might be more responsive to m<sup>7</sup>G modifications, while IGF2BP1 prefers m<sup>6</sup>A. Such difference is also consistent with our previous binding affinity results, implying that individual members of the IGF2BP family play varied roles in mRNA stability regulation based on their preference to certain modifications.</p><p id="Par23">We then performed functional enrichment analysis to illustrate the potential differences of the two modifications in biological functions (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">5h</xref>). m<sup>6</sup>A-modified transcripts enriched GO terms including protein ubiquitination, cell division, and transcription regulation, while m<sup>7</sup>G-modified transcripts are closely related to functions regarding cell cycle, chromatin remodeling, and mRNA regulation. Interestingly, the genes with both modifications highlighted the pathways of splicing and chromatin organization, indicating that the dual modifications might allow more flexible regulations on the transcription and splicing.</p></sec><sec id="Sec8"><title>in vitro validation with dCas13b tethering systems</title><p id="Par24">As we have found that IGF2BP1 and IGF2BP3 could promote the degradation of m<sup>7</sup>G-marked transcripts, we took advantage of the catalytically inactive RNA-targeting CRISPR-Cas13 systems<sup><xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref></sup> to site-specifically manipulate m<sup>7</sup>G methylation and IGF2BPs binding. The nuclease inactivated Cas13 system (dCas13) has been widely used to manipulate the methylation level, with either writer or eraser fused, and has also been used to investigate the reader binding effects on m<sup>6</sup>A transcripts. We therefore fused the dCas13b system with IGF2BP3 as the reader representative or METTL1 as the writer (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>) and tested whether these tethering constructs could affect the half lifetime of selected transcripts.<fig id="Fig4"><label>Fig. 4</label><caption><title>Application of the dCas13b-tethering systems for cell-based validation and mechanistic studies.</title><p><bold>a</bold> Schematic diagram showing the modified dCas13b system with IGF2BP3 (dCas13b-IGF2BP3, left) and METTL1 (dCas13b-METTL1, right). <bold>b</bold> Relative m<sup>7</sup>G methylation levels of the selected gene loci. Mean&#x02009;&#x000b1;&#x02009;SEM of three independent experiments. <bold>c</bold> Changes in mRNA levels in HepG2 cells with introduction of dCas13b-IGF2BP3 and guide RNA at the loci or not (neg). Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. Calculated half lifetimes are marked in the corresponding colors. <bold>d</bold> Relative m<sup>7</sup>G methylation level of the loci of the selected genes upon introducing the dCas13b-METTL1 tethering with the guide RNAs at the target loci or not (neg), normalized to the methylation level in the wildtype cells. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <italic>P</italic>-values are marked at the top of each group. <bold>e</bold> Changes in mRNA levels in HepG2 cells with the introduction of dCas13b-METTL1 and the guide RNAs at the loci or not (neg). Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. Calculated half lifetimes are marked in the corresponding colors. <bold>f</bold> Western blotting of EXOSC2 in cell lysate from in vitro pulldown in HepG2 cells using the antibodies that recognize IGF2BP1, IGF2BP2, or IGF2BP3. Rabbit IgG was used as a negative control. This experiment was repeated independently twice with similar results. <bold>g</bold> mRNA levels of the m<sup>7</sup>G targets upon IGF2BP3 overexpression, or <italic>EXOSC2</italic> knockdown, or both. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. All source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2024_51634_Fig4_HTML" id="d33e1674"/></fig></p><p id="Par25">We picked several representative targets with methylation loci identified (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>) and binding sites of IGF2BP proteins, especially IGF2BP3, near the methylation peaks (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">4e</xref>). These transcripts showed decreases in half lifetime when targeted by IGF2BP3 at the methylated loci rather than the unmethylated ones (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6a</xref>). As a control, the tethering of IGF2BP1 presented little effect (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6b</xref>), further indicating that IGF2BP3 is more responsive to m<sup>7</sup>G while IGF2BP1 is not. We also directed dCas13b-METTL1 to the transcripts with relatively lowly methylated loci. The tethering of METTL1 increased the methylation levels of the targeted regions (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>) and the binding intensity of IGF2BP3 on the transcripts based on the RNA immunoprecipitation (RIP) followed by qPCR quantification (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6c</xref>). Such increases also resulted in elevated degradation of the transcripts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6d</xref>). The elevated degradation induced by tethering with IGF2BP3 or METTL1 could be greatly attenuated upon knockdown of <italic>METTL1</italic> or <italic>IGF2BP3</italic>, respectively (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6e-f</xref>). We also applied the dCas13b system in cells with stable knockdown of <italic>METTL3</italic> and observed little difference compared to the control cells (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">6g-h</xref>). These results collectively suggest that both IGF2BP3 and m<sup>7</sup>G modifications are indispensable for the regulation of transcript degradation, and such regulation is independent of m<sup>6</sup>A.</p></sec><sec id="Sec9"><title>IGF2BP3 promotes the degradation of m<sup>7</sup>G targets through exosome complex</title><p id="Par26">We then asked how IGF2BP3 specifically promotes the degradation of the m<sup>7</sup>G-modified transcripts. IGF2BP3 has been reported to interact with XRN2 (5&#x02019;&#x02212;3&#x02019; exonuclease) and EXOSC2 (component of exosome complex) to promote the decay of the <italic>eIF4E-BP2</italic> mRNA<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. We therefore asked whether these two proteins are also involved in the m<sup>7</sup>G-dependent mRNA decay through IGF2BP3. Both XRN2 and EXOSC2 were enriched by the immunoprecipitation of the IGF2BP proteins (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4f</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7a</xref>). The former showed a higher interaction level with IGF2BP2 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7a</xref>), while EXOSC2 is more closely interacted with IGF2BP1 and IGF2BP3 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4f</xref>). Exosome complex is involved in many biology processes and EXOSC2 is known to located at the cap of the complex<sup><xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref></sup>. We next tested the association of IGF2BP proteins with other exosome complex components that are closely connected to EXOSC2. We found that when bound by EXOSC2, IGF2BP1 and IGF2BP3 form a close interaction with EXOSC4, EXOSC7, and EXOSC3, components close in location with EXOSC2 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7b</xref>). These results suggested that m<sup>7</sup>G targets bound by IGF2BPs might be recognized and delivered to exosome complex through their interaction with EXOSC2 for accelerated degradation. To verify this, we knocked down <italic>EXOSC2</italic> in IGF2BP3 overexpressed HepG2 cells (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7c</xref>) and observed that the decreased mRNA expression levels upon IGF2BP3 overexpression could be recovered by EXOSC2 downregulation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4g</xref>), supporting the involvement of EXOSC2 and exosome in the IGF2BP3-mediated transcript decay.</p></sec><sec id="Sec10"><title>IGF2BP3 is involved in glioma and regulates the decay of <italic>TP53</italic> transcripts</title><p id="Par27">As we have identified IGF2BP family as the binding proteins of internal m<sup>7</sup>G and can promote decay of the target transcripts, we asked if IGF2BPs, especially IGF2BP3, are involved in the regulation of m<sup>7</sup>G methylation in glioma given the correlation with METTL1 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). When we performed the gene ontology (GO) enrichment analysis with the transcripts targeted by IGF2BPs but only modified by m<sup>7</sup>G, we noticed that the glioma pathway and the terms about cell cycle arrest and p53 pathways were both highlighted (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8a</xref>), so as other pathways closely related to p53, implying that IGF2BPs affect p53-related genes, especially in glioma, and this process might go through regulation on m<sup>7</sup>G-modified transcripts. IGF2BP3 is also highly correlated with the glioma term (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8b</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><title>Regulation of IGF2BP3 on m<sup>7</sup>G-marked transcripts in glioblastoma cells.</title><p><bold>a</bold> Gene Set Enrichment Analysis (GSEA) of genes in &#x02018;Glioma&#x02019; KEGG pathway against ranked list of genes according to half lifetime changes upon <italic>IGF2BP3</italic> knockdown. <bold>b</bold> Kaplan-Meier survival analysis in TCGA database for Glioma (TCGA-GBMLGG) with wildtype <italic>TP53</italic> (left), or with mutant <italic>TP53</italic> (right). The patients were divided into two groups of equal size based on <italic>IGF2BP3</italic> levels. <italic>P</italic>-value detected by log-rank test. <bold>c</bold> Changes in <italic>TP53</italic> mRNA level in highly methylated cells upon <italic>IGF2BP3</italic> knockdown. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. Calculated half lifetimes marked in corresponding colors. <bold>d</bold>&#x02013;<bold>f</bold> Relative m<sup>7</sup>G levels of the <italic>TP53</italic> 3&#x02019; UTR locus upon <italic>METTL1</italic> knockdown (<bold>d</bold>), IGF2BP3 overexpression (<bold>e</bold>), and <italic>IGF2BP3</italic> knockdown (<bold>f</bold>), normalized to the methylation level in the corresponding control cells. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>g</bold> Changes in mRNA levels in cells with introduction of dCas13b-IGF2BP3 or dCas13b-METTL1 and <italic>TP53</italic> gRNA at the loci or not (neg). Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. Calculated half lifetimes marked in corresponding colors. <bold>h</bold> Relative m<sup>7</sup>G levels of the <italic>TP53</italic> 3&#x02019; UTR locus with introduction of dCas13b-IGF2BP3 or dCas13b-METTL1 and <italic>TP53</italic> gRNA at the loci or not (neg), normalized to the methylation level in wildtype cells. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>i</bold> Relative <italic>TP53</italic> mRNA levels in cells with dCas13b-IGF2BP3 or dCas13b-METTL1 and the guide RNA, normalized to the cells with negative gRNA. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;3) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>j</bold> Western blot of p53 levels in T98G cells with dCas13b-IGF2BP3 or dCas13b-METTL1 tethering with the guide RNA or the negative gRNA. <bold>k</bold> Cell proliferation in LN229 cells with dCas13b-IGF2BP3 tethering with the guide RNA or the negative gRNA. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;6) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>l</bold> Western blot of MGMT levels in T98G cells with dCas13b-IGF2BP3 tethering with the guide RNA compared to negative gRNA and wildtype cells. <bold>m</bold> Survival percentages of T98G cells treated TMZ at different concentrations with dCas13b-IGF2BP3 tethering with the guide RNA, or the negative gRNA, compared to wildtype cells. Mean&#x02009;&#x000b1;&#x02009;SEM (<italic>n</italic>&#x02009;=&#x02009;6) with two-tailed Student&#x02019;s <italic>t</italic>-tests. <bold>j</bold> and (<bold>l</bold>) were both repeated independently twice with similar results. All source data are provided as a Source Data file.</p></caption><graphic xlink:href="41467_2024_51634_Fig5_HTML" id="d33e1965"/></fig></p><p id="Par28">Similar to METTL1, IGF2BP3 is highly expressed in tumors compared to normal tissues across various cancer types, with glioblastoma ranked second (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8c</xref>). Notably, among the proteins involved in m<sup>7</sup>G regulation in glioblastoma, IGF2BP3 is the most upregulated one in tumor versus normal tissues (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8d</xref>). In addition, higher expression of IGF2BP3 is also correlated to lower overall survival rate in glioma/glioblastoma (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8e</xref>). Such correlation on the survival rate also dramatically diminished in patients with mutated p53 compared to those with wildtype p53 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5b</xref>). All these correlations between IGF2BP3 with glioma and glioblastoma as well as the oncogenic functions of METTL1 in these tumors indicate that METTL1 might act as a critical player in tumorigenesis not only through m<sup>7</sup>G-modified tRNAs as previously reported<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>, but also through internal m<sup>7</sup>G modifications within mRNAs and the mRNA m<sup>7</sup>G regulation by IGF2BP3.</p><p id="Par29">We first confirmed that the methylated peak at the 3&#x02019;UTR of <italic>TP53</italic> overlaps well with the IGF2BP3 binding (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9a</xref>). In HepG2 cells, where the 3&#x02019; UTR of <italic>TP53</italic> is moderately methylated, we knocked down <italic>IGF2BP3</italic> and observed a slower <italic>TP53</italic> decay (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9b</xref>). Based on our previous quantification of the methylation level, we grouped the four glioblastoma cell lines into highly (U87MG and LN229) and lowly (A172 and T98G) m<sup>7</sup>G-methylated groups. All cell lines presented significant increases in the half lifetime of <italic>TP53</italic> transcript upon <italic>IGF2BP3</italic> knockdown (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5c</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9c</xref>). We then performed knockdown of <italic>METTL1</italic> in the highly methylated group. We observed a consistent decrease of the m<sup>7</sup>G level in the 3&#x02019; UTR of <italic>TP53</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5d</xref>), which confirmed <italic>TP53</italic> as an METTL1 target. Also, in the highly methylated group, the overexpression of IGF2BP3 led to a dramatic decrease in the methylation level of <italic>TP53</italic> at its 3&#x02019; UTR locus, especially in LN229 (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5e</xref>), where the IGF2BP3 protein is limited (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9d</xref>). The overexpression of IGF2BP3 would specifically promote the degradation of m<sup>7</sup>G targets compared to the non-methylated ones, and thus decrease the relative methylation level of <italic>TP53</italic> at its 3&#x02019; UTR region. Correspondingly, in the lowly methylated group, <italic>IGF2BP3</italic> knockdown resulted in increased <italic>TP53</italic> m<sup>7</sup>G methylation levels (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5f</xref>).</p><p id="Par30">As cells in the highly methylated group are more sensitive to IGF2BP3 overexpression, we further validated our decay mechanism in these cell lines (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9e</xref>). As expected, the transcript level of <italic>TP53</italic> was recovered upon <italic>EXOSC2</italic> knockdown in IGF2BP3 overexpressed cells (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9f</xref>), supporting that IGF2BP3 tunes <italic>TP53</italic> stability through the EXOSC2-mediated pathway. These results implied that in glioblastoma cells, IGF2BP3 could regulate the <italic>TP53</italic> transcript level through its recognition and action on the m<sup>7</sup>G at its 3&#x02019; UTR. To establish a causal relationship, we directed dCas13b-fusion systems to the <italic>TP53</italic> 3&#x02019; UTR locus in glioblastoma. The transcript targeted by IGF2BP3 was more rapidly decayed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5g</xref>, left, and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9g</xref>, left), which is consistently observed across the tested cell lines. In the cells with lowly methylated 3&#x02019; UTR, the tethering of METTL1 increased the methylation level in the locus of <italic>TP53</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5h</xref>), which also led to a more rapid degradation of <italic>TP53</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5g</xref>, right, and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9g</xref>, right).</p></sec><sec id="Sec11"><title>Downregulation of <italic>TP53</italic> by m<sup>7</sup>G and IGF2BP3 affects cell proliferation and chemoresistance</title><p id="Par31">The introduction of dCas13b systems to <italic>TP53</italic> in the glioblastoma cells, fused with either IGF2BP3 or METTL1, not only suppressed the transcript level (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5i</xref>), but also led to a decreased p53 protein level (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5j</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9h</xref>), with dCas13b-IGF2BP3 showing more decreases. As p53 is widely involved in cancer regulation, we further validated the effects of the downregulated <italic>TP53</italic> on related pathways.</p><p id="Par32">The wildtype p53 plays an important role in cell cycle regulation. Considered as the guardian of genome, p53 is highly involved in DNA damage repair, cell cycle regulation, and apoptosis<sup><xref ref-type="bibr" rid="CR60">60</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref></sup>. The p53 pathway has previously shown to be regulated through mRNA modifications such as m<sup>6</sup>A<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. In LN229 cells with partially functional p53<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, or U87MG cells with wild-type p53, the downregulation of p53 level triggered by the dCas13b-IGF2BP3 tethering system could promote cell proliferation (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5k</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9i</xref>), in a similar way to the knockdown of <italic>TP53</italic> using siRNA transfection (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9j</xref>) or overexpression of IGF2BP3 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9k</xref>). The decreased protein level of p53 upon dCas13b-IGF2BP3 tethering also led to a decreased percentage of G0/G1 cells, suggesting an increased level of cells escaping G1 arrest (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9l-m</xref>). Such results are consistent with the role of p53 for arrest induction in regulation cell cycle checkpoint.</p><p id="Par33">Besides cells with wildtype p53, we also investigated the gain of function p53 mutant in the T98G cells. T98G is a well-studied TMZ resistant cells with IC50 usually over 500&#x02013;1000&#x02009;&#x000b5;M<sup><xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref></sup>. The mutant p53 in T98G cells elevated the expression level of O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT), a key regulator in DNA damage repair, and thus promoted TMZ resistance<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. We picked the dCas13b-IGF2BP3 tethering system where p53 proteins were more downregulated and validated that both the mRNA level (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9n</xref>) and protein expression (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5l</xref>) of MGMT were decreased upon introduction of dCas13b-IGF2BP3 with the guide RNA. We then continued with the TMZ resistance test. The wildtype cells presented a generally high resistance towards TMZ treatment. However, T98G cells introduced with dCas13b-IGF2BP3 and the guide RNA demonstrated a noticeable decrease in TMZ resistance (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5m</xref>), which is also observed upon IGF2BP3 overexpression (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">9o</xref>), confirming a regulation of p53 function through the internal m<sup>7</sup>G methylation.</p><p id="Par34">Altogether, our results revealed that the IGF2BP family proteins could recognize mRNA internal m<sup>7</sup>G modification. The binding of IGF2BP3 and IGF2BP1 could promote the decay of m<sup>7</sup>G-modified transcripts, with IGF2BP3 exhibiting a higher preference to m<sup>7</sup>G and more effects on target transcript decay. In glioblastoma, we show that the tuning of m<sup>7</sup>G methylation in the 3&#x02019; UTR of <italic>TP53</italic> could manipulate the mRNA and protein levels of p53, which affected cancer cell proliferation or chemoresistance.</p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p id="Par35">The internal m<sup>7</sup>G modification has been found to impact biological processes through tRNA and rRNA. While the single-base resolution maps of internal m<sup>7</sup>G at the whole transcriptome level are available, it remains underexplored whether the positive-charged mRNA modification plays any role in the mRNA regulation and the underlying pathways. Here, we identified the IGF2BP family proteins as the binding proteins of the mRNA internal m<sup>7</sup>G in cancer cells. The recognitions of m<sup>7</sup>G by&#x000a0;IGF2BP1 and IGF2BP3 promote the degradation of the methylated transcripts, with IGF2BP3 more responsive to the modification. We found that <italic>TP53</italic> is m<sup>7</sup>G-modified in its 3&#x02019; UTR with varied methylation levels across glioblastoma cell lines; the methylation is also negatively correlated with transcript expression level across these glioblastoma cell lines, suggesting a destabilization effect. The tethering of METTL1 or IGF2BP3 to <italic>TP53</italic> led to downregulation of <italic>TP53</italic> expression, respectively, leading to changes of cell proliferation and chemoresistance.</p><p id="Par36">Both METTL1 and IGF2BP3 are highly expressed in glioblastoma, and their upregulations are associated with poor survival in patients. The correlation was more obvious in patients with wildtype p53 but diminished in the mutant ones. Here, based on our results, the upregulation of both METTL1 and IGF2BP3 could lead to degradation of <italic>TP53</italic> transcripts and thus decreased p53 protein level. The downregulation of functional wildtype p53 would promote tumor progression. <italic>TP53</italic> is one of the most frequently mutated genes in tumors and can protect cancer cells from oxidative and proteotoxic stresses. Loss-of-function or gain-of-function mutants could lead to diverse effects in different tumors. We also included our study in T98G cells with a gain-of-function <italic>TP53</italic> where the m<sup>7</sup>G methylation of the mutant <italic>TP53</italic> transcript increased its chemosensitivity to temozolomide, showcasing consistent transcript decay effect of m<sup>7</sup>G and IGF2BP3 in cancer lines with diverse <italic>TP53</italic> status. We also performed active mRNA translation sequencing (ART-seq) to capture actively translating transcripts upon <italic>IGF2BP3</italic> knockdown (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10a</xref>) and validated the protein expression level changes of the representative targets in both HepG2 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10b</xref> and <xref rid="MOESM1" ref-type="media">10c</xref>) and other cancer cell lines (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">10d</xref> and <xref rid="MOESM1" ref-type="media">10e</xref>). While <italic>IGF2BP3</italic> knockdown impaired the translation of m<sup>6</sup>A targets as previously reported<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, IGF2BP3 depletion generally elevated transcript levels of m<sup>7</sup>G targets but presented limited impact on their translation, further suggesting its regulatory role on m<sup>7</sup>G targets in mRNA decay.</p><p id="Par37">Human IGF2BP proteins share about 56% overall sequence identity and the identity increases to around 70% when only considering the RNA binding domains<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Though they share similar amino acid sequences, they differed in the RNA modification recognition as revealed in our study. While IGF2BP2 mostly recognizes m<sup>6</sup>A, IGF2BP1 and IGF2BP3, particularly IGF2BP3, could promote decay of the m<sup>7</sup>G-modified target transcripts. Although differences in binding motif preferences may partially account for their binding diversity, detailed elucidation of their structural alterations and potential protein interactions upon binding with distinct RNA modifications will allow a comprehensive understanding of diverse regulatory roles of IGF2BP proteins. IGF2BP1 and IGF2BP3 are more homologous to each other and display limited expression levels in adult organs except for the reproductive tissues. On the contrary, IGF2BP2 is widely expressed in various adult tissues. These all suggest that IGF2BP family proteins could play diverse roles on mRNA based on their distinct expressions and binding preferences. These regulations could be cell context dependent. Certain cancer cells may possess higher abundances of mRNA internal m<sup>7</sup>G and thus&#x000a0;be subjected to stronger IGF2BP3 regulation through m<sup>7</sup>G.</p><p id="Par38">While all IGF2BP family members recognize both m<sup>7</sup>G and m<sup>6</sup>A modifications, we observed an opposite trend for regulation on mRNA degradation where m<sup>7</sup>G seems to add another layer of regulation. The dynamics of transcripts bearing these modifications may vary, even when they are recognized by the same protein, due to changes in the abundance or activity of these regulatory factors. Alterations in local motifs and structural arrangements near a modified site may also readily modulate its access to specific reader proteins. Additionally, the localization of binding sites, whether within coding sequence (CDS) or untranslated regions (UTRs), could influence the regulatory pathways. Interestingly, our analysis revealed that while the interactions between IGF2BPs and m<sup>6</sup>A or m<sup>7</sup>G both predominantly occur in the 3&#x02019;UTR, the overlapped peaks of IGF2BPs and m<sup>6</sup>A are mainly concentrated near the stop codon. Conversely, interactions with m<sup>7</sup>G span across the entire 3&#x02019;UTR, implying that IGF2BP proteins might bind to different modifications at distinct regions within the 3&#x02019;UTR. This potentially could lead to recruitment of different partners for RNA regulation, likely in different cell types and cell contexts.</p><p id="Par39">In addition to the decay function shown in this study, previous reports discovered that internal m<sup>7</sup>G, especially those as METTL1 targets, could promote translation of modified transcripts. Unlike m<sup>6</sup>A, m<sup>7</sup>G tends to enrich in the CDS region<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. While IGF2BPs mainly bind to 3&#x02019; UTR and regulate mRNA decay, the m<sup>7</sup>G in the CDS might act in a different way through interaction with ribosome and affect translation. METTL1 may only account for a subset of the internal m<sup>7</sup>G installation, other writer(s) might also be involved and regulate certain targets. Deciphering the regulators and the functions of internal m<sup>7</sup>G should allow better understanding of the overall orchestration of mRNA regulation pathways through different modifications in mammalian processes and disease development.</p></sec><sec id="Sec13"><title>Methods</title><sec id="Sec14"><title>Cells culture</title><p id="Par40">Human HepG2, A172, LN229, T98G, and U87MG cell lines used in this study were all purchased from ATCC (the American Type Culture Collection). HepG2 and A172 cell lines were grown in DMEM (Gibco, 11995) media supplemented with 10% FBS and 1% 100X Pen/Strep (Gibco). LN229 cell line was grown in DMEM (Gibco, 11995) media supplemented with 5% FBS and 1% 100X Pen/Strep (Gibco). T98G and U87MG cell lines were maintained in EMEM (ATCC, 30-2003), supplemented with 10% FBS and 1% 100X Pen/Strep (Gibco). All cells were cultured at 37&#x02009;&#x000b0;C under 5.0% CO<sub>2</sub>. To construct the METTL3 knockdown and control cell lines, we used the TRC Lentiviral Human shRNA system encoding a control shRNA or a shRNAs targeting METTL3 (TRCN0000034715).</p></sec><sec id="Sec15"><title>Antibodies</title><p id="Par41">The antibodies used in this study are listed below in the format of name (catalog; supplier; dilution fold): Mouse anti-m<sup>7</sup>G (RN017M; MBL; 1000; clone 4141-13). Rabbit anti-METTL1 (14994-1-AP; Proteintech; 1000). Rabbit anti-m<sup>6</sup>A (E1610S; NEB; 1000). Mouse anti-WDR4 (sc-100894; Santa Cruz; 100). Rabbit anti-IGF2BP1 (8482; Cell Signaling; 1000). Rabbit anti-IGF2BP2 (14672; Cell Signaling; 1000). Rabbit anti-IGF2BP3 (57145; Cell Signaling; 1000). Rabbit anti-EXOSC2 (ab181211; Abcam; 10000). Mouse anti-EXOSC3 (sc-166568; Santa Cruz; 100). Mouse anti-EXOSC4 (sc-166772; Santa Cruz; 100). Mouse anti-EXOSC7 (sc-393686; Santa Cruz; 100). Rabbit anti-XRN2 (13760; Cell Signaling; 1000). Mouse anti-p53 (sc-126; Santa Cruz; 100). Mouse anti-MGMT (sc-166528; Santa Cruz; 100). Mouse Anti-BrdU (B2531; Sigma; 100; clone BU-33). Goat Anti-Mouse IgG H&#x00026;L (Alexa Fluor&#x000ae; 488) (ab150113; Abcam; 2000). Goat anti-rabbit lgG-HRP (7074; Cell Signaling; 3000). Horse anti-mouse lgG-HRP (7076; Cell Signaling; 3000). Rabbit anti-GAPDH-HRP (8884; Cell Signaling; 1000).</p></sec><sec id="Sec16"><title>RNA isolation</title><p id="Par42">Generally, to isolate total RNA from cells, the media was aspirated, and the cells were washed once with a proper volume of ice-cold DPBS buffer for each plate. Then total RNA was isolated from cells with TRIzol reagent (Invitrogen) and then extracted following the manufacturer&#x02019;s protocol through isopropanol precipitation. GlycoBlue Coprecipitant (15&#x02009;mg&#x02009;ml<sup>&#x02212;1</sup>, Thermo Fisher Scientific) was added to the solution during precipitation if needed. mRNA enrichment: starting from extracted total RNA, mRNA was purified with two rounds of polyA<sup>+</sup> purification with Dynabeads mRNA DIRECT kit (Ambion). RNA concentration was measured by UV absorbance at 260&#x02009;nm or using Qubit RNA HS Assay Kit (Thermo Fisher Scientific) with Qubit 2.0 fluorometer.</p></sec><sec id="Sec17"><title>LC-MS/MS</title><p id="Par43">Around 200-300&#x02009;ng mRNA was digested first with nuclease S1 (1uL, Sigma) in a 20&#x02009;&#x000b5;L reaction buffer containing 10&#x02009;mM of NH<sub>4</sub>OAc (pH&#x02009;=&#x02009;5.3) at 42&#x02009;&#x000b0;C for 2&#x02009;h. Then, 1&#x02009;&#x000b5;L of shrimp alkaline phosphatase (rSAP, NEB) was added along with 2.5&#x02009;&#x000b5;L of 10X CutSmart buffer (NEB) and incubated at 37&#x02009;&#x000b0;C for 2&#x02009;h. After the incubation, the sample was diluted with additional 35&#x02009;&#x000b5;L water and filtered with 0.22&#x02009;&#x000b5;m filters (4&#x02009;mm diameter, Millipore) and 8&#x02009;&#x000b5;l of the entire solution was injected into LC-MS/MS as one sample. For all the quantification, a mock control with only the digestion buffers and enzymes and water was included each time. The signals from the mock control would be later subtracted from the signals from experimental samples as the baseline. Nucleosides were separated, by reverse-phase ultra-performance liquid chromatography, on a C1 column with on-line mass spectrometry detection by an Agilent 6410 QQQ triple-quadrupole LC mass spectrometer, in positive electrospray ionization mode. The nucleosides were quantified with retention time and the nucleoside-to-base ion mass transition of 284-152 (G), 268-136 (A), 298.1-166.1 (m<sup>7</sup>G). Quantification was performed in comparison with the standard curve, obtained from pure nucleoside standards running with the same batch of samples. The m<sup>7</sup>G level was calculated as the ratio of m<sup>7</sup>G to G based on calibrated concentration curves.</p></sec><sec id="Sec18"><title>Decapping of mRNA</title><p id="Par44">Decapping of mRNA was performed with Tobacco Decapping Plus 2 (#94, Enzymax). The reaction was prepared, with a maximum of 6&#x02009;&#x000b5;g fragmented mRNA in nuclease-free water with 5&#x02009;&#x000b5;L 10X Decapping Reaction Buffer (100&#x02009;mM Tris-HCl pH 7.5, 1.0&#x02009;M NaCl, 20&#x02009;mM MgCl<sub>2</sub>, 10&#x02009;mM DTT), 1uL 50&#x02009;mM MnCl<sub>2</sub>, 2.5&#x02009;&#x000b5;L SUPERase-In RNase Inhibitor (Thermo Fisher Scientific) and 8&#x02009;&#x000b5;L Tobacco Decapping Plus 2 enzymes, diluted to a final volume of 50&#x02009;&#x000b5;L. The reaction was incubated at 37&#x02009;&#x000b0;C for 2&#x02009;h. Decapped RNA was extracted from the solution with RNA Clean &#x00026; Concentrator (Zymo Research).</p></sec><sec id="Sec19"><title>Western blot</title><p id="Par45">Samples were homogenized in CelLytic M buffer (Sigma) containing 1&#x02009;&#x000d7;&#x02009;protease inhibitor cocktail (Roche) on ice for at least 15&#x02009;min. The lysates were then centrifuged to remove the cellular debris and boiled at 95&#x02009;&#x000b0;C with 4&#x02009;&#x000d7;&#x02009;loading buffer (Bio-Rad) for 5&#x02009;min and stored at &#x02013;80&#x02009;&#x000b0;C for later use in the next step. 5&#x02009;&#x003bc;g or more total protein amount per sample was loaded into 4&#x02013;12% NuPAGE Bis-Tris gel (Life Technologies) and transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked in 5% milk in TBST for 30&#x02009;min at room temperature, incubated in a diluted primary antibody solution at 4&#x02009;&#x000b0;C overnight, washed and incubated in a dilution of secondary antibody conjugated to HRP for 1&#x02009;h at room temperature. Protein bands were detected with SuperSignal West Dura Extended Duration Substrate kit (Thermo) or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo) if needed and FluroChem R (Proteinsimple).</p></sec><sec id="Sec20"><title>EMSA (electrophoretic mobility shift assay/gel shift assay)</title><p id="Par46">The RNA probes were synthesized with MEGAshortscript T7 Transcription Kit (Thermo) based on the sequence of 5&#x02019;- CCAATAAAATATTAACCACCAATAAAATATTAACCAA<underline>Z</underline>ATCCACCAATAAAATATTAACC-3&#x02019; (<underline>Z</underline>&#x02009;=&#x02009;G or m<sup>7</sup>G) with either GTP (included in the kit) or m<sup>7</sup>GTP (Sigma, dissolve as 75&#x02009;mM). After the synthesis, the RNA probe was labeled with T4 RNA ligase 1 (NEB) and pCp-Cy3 (Jena Bioscience), following the manufacturer&#x02019;s protocol. The RNA probes were denatured at 65&#x02009;&#x000b0;C for 4&#x02009;min, and then quickly cooled on ice. FLAG&#x02013;IGF2BP1, FLAG&#x02013;IGF2BP2, and FLAG&#x02013;IGF2BP3 were purified with overexpression in HEK293T cells followed by FLAG-tag pulldown with anti-Flag M2 magnetic beads (Sigma) following commercial protocol. The protein purifications were validated with 4-12% NuPAGE Bis-Tris gel running followed by protein staining with Imperial Protein Stain (Thermo). The proteins were diluted to the desired concentration series in binding buffer (10&#x02009;mM HEPES, pH 8.0, 50&#x02009;mM KCl, 1&#x02009;mM EDTA, 0.05% Triton-X-100, 5% glycerol, 10&#x02009;&#x003bc;g&#x02009;ml<sup>&#x02013;1</sup> salmon DNA, 1&#x02009;mM DTT and 40&#x02009;U&#x02009;ml<sup>&#x02013;1</sup> RNasin). Before loading to each well, 1&#x02009;&#x000b5;l RNA probe (4&#x02009;nM final concentration) and 1&#x02009;&#x000b5;l protein (20&#x02009;nM, 50&#x02009;nM, 100&#x02009;nM, 200&#x02009;nM, 300&#x02009;nM or 1&#x02009;&#x003bc;M final concentration) were added and the solution was incubated on ice for 30&#x02009;min. The entire 10&#x02009;&#x000b5;l RNA&#x02013;protein mixture was loaded to the Novex 4-20% TBE gel (Invitrogen) and run at 4&#x02009;&#x000b0;C for 90&#x02009;min at 90&#x02009;V. Imaging was carried out by Bio-Rad Molecular Imager FX under Cy3 channel.</p></sec><sec id="Sec21"><title>in vitro pulldown for western and protein mass spectrometry</title><p id="Par47">Probes were prepared through in vitro transcription as described before. After the synthesis and cleanup with RNA Clean and Concentrator (Zymo Research), the RNA probes were labeled by Pierce RNA 3&#x02019; End Biotinylation Kit (Thermo) followed by purification with RNA Clean and Concentrator (Zymo Research). The m<sup>6</sup>A and A probes (5&#x02019;- GAACCGG<underline>X</underline>CUGUCUUA-3&#x02019; (<underline>X</underline>&#x02009;=&#x02009;A or m<sup>6</sup>A)) were synthesized directly with biotin tag at 5&#x02019; end. HepG2 cells were collected (one 15-cm plate) by cell lifter (Corning Incorporated), pelleted by centrifuge for 5&#x02009;min at 500&#x02009;g and washed once with cold PBS (6&#x02009;ml). The cell pellet was re-suspended with 2 volumes of lysis buffer (250&#x02009;mM NaCl, 10&#x02009;mM Tris-HCl pH 7.6, 0.5% NP-40, 10% glycerol, 1:100 protease inhibitor cocktail, 400&#x02009;U&#x02009;ml<sup>&#x02013;1</sup> RNase inhibitor) and mixed with rotation at 4&#x02009;&#x000b0;C for 30&#x02009;min. The mixture was then centrifuged at 15,000&#x02009;g for 15&#x02009;min to clear the lysate. 50&#x02009;&#x000b5;l cell lysate was saved as input. The rest was divided into two tubes with equal volume. 1&#x02009;&#x000b5;g&#x02009;G or m<sup>7</sup>G probes were added to the tubes. The probe and cell lysate were then rotated continuously at 4&#x02009;&#x000b0;C for 2&#x02009;h. 20&#x02009;&#x000b5;l Dynabeads MyOne Streptavidin C1 beads (Invitrogen) were washed for each sample with the lysis buffer and then added to the mixture, and underwent another 2&#x02009;h incubation at 4&#x02009;&#x000b0;C. The beads were collected and washed five times with 1&#x02009;ml ice-cold lysis buffer. The beads were sent directly to MS Bioworks for protein mass spectrometry analysis or boiled with 40&#x02009;&#x000b5;l 1X loading buffer (Bio-Rad) (diluted with PBS) at 95&#x02009;&#x000b0;C for 5&#x02009;min, followed by western blot analyses.</p><p id="Par48">For protein mass spectrometry, two samples were processed, one for G probe as control, and the other for m<sup>7</sup>G probe. The samples were eluted in reducing LDS buffer at 100&#x02009;&#x000b0;C for 15&#x02009;min. Half of each sample was processed by SDS-PAGE using 10% Bis-Tris NuPage Mini-gel (Invitrogen) with the MES buffer system. The gel was run 1&#x02009;cm and the mobility region excised into 10 equally sized bands. Each band was processed by in-gel digestion with trypsin using a robot (ProGest, DigiLab) with the following protocol: (1) washed with 25&#x02009;mM ammonium bicarbonate followed by acetonitrile; (2) reduced with 10&#x02009;mM dithiothreitol at 60&#x02009;&#x000b0;C followed by alkylation with 50&#x02009;mM iodoacetamide at room temperature; (3) digested with sequencing grade trypsin (Promega) at 37&#x02009;&#x000b0;C for 4&#x02009;h; (4) Quenched with formic acid and the supernatant was analyzed directly without further processing. Half of each digested sample was analyzed by nano LC-MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher Fusion Lumos mass spectrometer. Peptides were loaded on a trapping column and eluted over a 75&#x02009;&#x000b5;m analytical column at 350 nL/min; both columns were packed with Luna C18 resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with the Orbitrap operating at 60,000 FWHM and 15,000 FWHM for MS and MS/MS respectively. The instrument was run with a 3&#x02009;s cycle for MS and MS/MS. 5-h instrument time was used for the analysis of each sample. Data were searched using a local copy of Mascot (Matrix Science) with the following parameters: Enzyme: Trypsin/P; Databases: SwissProt Human (concatenated forward and reverse plus common contaminants); Fixed modifications: Carbamidomethyl (C); Variable modifications: Acetyl (N-term), Deamidation (N,Q), Oxidation (M), Pyro-Glu (N-term Q); Mass values: Monoisotopic; Peptide Mass Tolerance: 10 ppm; Fragment Mass Tolerance: 0.02&#x02009;Da; Max Missed Cleavages: 2. Mascot DAT files were parsed into Scaffold (Proteome Software) for validation and filtered to create a non-redundant list per sample. Data were filtered at 1% protein and peptide FDR. At least two unique peptides are required per protein.</p></sec><sec id="Sec22"><title>Protein coimmunoprecipitation</title><p id="Par49">HepG2 cells were collected by cell lifter (one 15&#x02009;cm plate), and pelleted by centrifuge at 500&#x02009;g for 5&#x02009;min. The cell pellet was resuspended with 2 volumes of lysis buffer (150&#x02009;mM KCl, 10&#x02009;mM HEPES pH 7.6, 2&#x02009;mM EDTA, 0.5% NP-40, 0.5&#x02009;mM DTT, 1:100 protease inhibitor cocktail, 400&#x02009;U&#x02009;ml<sup>&#x02013;1</sup> RNase inhibitor), and incubated on ice for 30&#x02009;min. To remove the cell debris, the lysate solution was centrifuged at 15,000&#x02009;g for 15&#x02009;min at 4&#x02009;&#x000b0;C. While 50&#x02009;&#x000b5;l of cell lysate was saved as the input, the rest was incubated with the anti-IGF2BP1 or anti-IGF2BP3 antibodies for 2&#x02009;h at 4&#x02009;&#x000b0;C. Afterwards, Protein A beads (Invitrogen) were washed and added to the mixtures with another 2&#x02009;h incubation at 4&#x02009;&#x000b0;C. The beads were then washed with ice-cold NT2 buffer (200&#x02009;mM NaCl, 50&#x02009;mM HEPES pH 7.6, 2&#x02009;mM EDTA, 0.05% NP-40, 0.5&#x02009;mM DTT, 200&#x02009;U&#x02009;ml<sup>&#x02013;1</sup> RNase inhibitor) four times. The eluted samples, saved as IP, were analyzed along with the input samples by western blotting.</p></sec><sec id="Sec23"><title>Quantification of RNA methylation with m<sup>7</sup>G-IP and RT-qPCR</title><p id="Par50">We performed m<sup>7</sup>G-MeRIP enrichment followed by RT-qPCR to quantify the relative m<sup>7</sup>G methylation level or level changes of certain target m<sup>7</sup>G sites or the entire transcripts. 0.5&#x02009;&#x000b5;g purified polyA<sup>+</sup> RNA extracted from the cells of interest were fragmented (or not if using full length mRNA) with Biorupter Pico (Diagenode) sonication with 30&#x02009;s ON/ 30&#x02009;s OFF for 8 cycles. 1&#x02009;&#x003bc;L 1:100 diluted non-modified spike-in from EpiMark <italic>N</italic><sup>6</sup>-Methyladenosine Enrichment Kit (NEB)&#x000a0;was added to each sample, and&#x000a0;m<sup>7</sup>G-MeRIP was performed&#x000a0;with the methylation-specific antibody (MBL). 2&#x02009;&#x000b5;L anti-m<sup>7</sup>G antibody (MBL) in 250&#x02009;&#x000b5;L 1X IPP buffer (10&#x02009;mM Tris-Cl, pH&#x02009;=&#x02009;7.4; 150&#x02009;mM NaCl; 0.1% NP-40) with freshly added 5% SUPERase-In RNase inhibitor (Thermo Fisher Scientific) at 4&#x02009;&#x000b0;C for 2&#x02013;4&#x02009;h. Then 20&#x02009;&#x000b5;L Dynabeads Protein G resins (Thermo Fisher Scientific) were washed twice with 1X IPP buffer, resuspended in 20&#x02009;&#x000b5;L IPP buffer, and added to the antibody-RNA mixture for another 2&#x02009;h at 4&#x02009;&#x000b0;C. The resins were then washed with 1X IPP buffer at 4&#x02009;&#x000b0;C four times. RNA was finally eluted with Proteinase K (recombinant, PCR grade, EO0491, Thermo Fisher Scientific) digestion. 45&#x02009;&#x000b5;L 1X Proteinase K digestion buffer (2X recipe: 2% SDS, 12.5&#x02009;mM EDTA, 100&#x02009;mM Tris-Cl (pH&#x02009;=&#x02009;7.4), 150&#x02009;mM NaCl) with 5&#x02009;&#x000b5;L Proteinase K was used to resuspend the resins, and the solution was incubated at 55&#x02009;&#x000b0;C for 30&#x02009;min. The m<sup>7</sup>G-containing RNA was recovered with RNA Clean &#x00026; Concentrator (Zymo Research), reverse transcribed with PrimeScript RT Master Mix (Takara), and then subjected to RT-qPCR. The spike-in was used as a reference gene when performing qPCR.</p></sec><sec id="Sec24"><title>RNA-seq for mRNA lifetime</title><p id="Par51">Five 10-cm plates of HepG2 cells were transfected with IGF2BP1-3 siRNA or METTL1 siRNA or control siRNA at 30% confluency. After 6&#x02009;h, each 10-cm plate was re-seeded into three 6-cm plates, and each plate was controlled to afford the close numbers of cells. After 48&#x02009;h, actinomycin D was added to 5&#x02009;&#x003bc;g&#x02009;ml<sup>&#x02013;1</sup> at 6&#x02009;h, 3&#x02009;h, and 0&#x02009;h before collection. The total RNA was purified with TRIzol (Invitrogen) described before. ERCC RNA spike-in control (Ambion) was added to each sample (0.02&#x02009;&#x000b5;l per 1&#x02009;&#x000b5;g total RNA). The total RNA with spike-in controls were then purified to acquire mRNA and the libraries were constructed with SMARTer Stranded Total RNA-Seq Kit v2 (Takara) according to the manufacturer&#x02019;s protocols and subject to Illumina Nova Seq in single-end mode with 100 base pair per read.</p></sec><sec id="Sec25"><title>RNA lifetime measurement by qPCR</title><p id="Par52">Samples were prepared as RNA-seq for mRNA lifetime. Total RNAs were extracted from all the samples and non-modified spike-in from EpiMark <italic>N</italic><sup>6</sup>-Methyladenosine Enrichment Kit (NEB) was added if external control is needed. Total RNAs were reverse transcribed with PrimeScript RT Master Mix (Takara), and then subjected to RT-qPCR. The spike-in was used as a reference gene when performing qPCR.</p></sec><sec id="Sec26"><title>RT-qPCR</title><p id="Par53">Quantitative reverse transcription PCR (RT-qPCR) was used to assess the relative abundance of RNA. Total RNA or purified nonribosomal RNA was reverse transcribed with PrimeScript RT Master Mix (Takara) to obtain cDNA. qPCR was performed by using FastStart Essential DNA Green Master (Roche) in machine LightCycler 96 (Roche). GAPDH were used as internal controls in different cases. When external control needed, 1&#x02009;&#x000b5;L 1/50-1/200 diluted non-m<sup>6</sup>A spike-in from EpiMark <italic>N</italic><sup>6</sup>-Methyladenosine Enrichment Kit were added to each sample.</p></sec><sec id="Sec27"><title>dCas13b-IGF2BP3 and METTL1 reporter assay</title><p id="Par54">dCas13b plasmid was a gift from Dr. Bryan Dickson (University of Chicago). dCas13b-IGF2BP3 and dCas13b-METTL1 were generated accordingly. The plasmids were sequenced by the University of Chicago Comprehensive Cancer Center DNA Sequencing and Genotyping Facility. For 6-well assays, cells were transfected with 1&#x02009;&#x003bc;g dCas13b proteins and 1.5&#x02009;&#x003bc;g gRNA for 24&#x02009;hr before analysis.</p></sec><sec id="Sec28"><title>Cell proliferation assay</title><p id="Par55">5000 cells were seeded per well in a 96-well plate. The cell proliferation was assessed by assaying cells at various time points using the CellTiter 96&#x000ae; Aqueous One Solution Cell Proliferation Assay (Promega) following the manufacturer&#x02019;s protocols. For each sample tested, the signal from the MTS assay was normalized to the value observed at ~5 or 24&#x02009;h after seeding.</p></sec><sec id="Sec29"><title>Cell cycle analysis</title><p id="Par56">LN229 and U87MG cells were labeled with BrdU (10&#x02009;&#x003bc;M) for 30&#x02009;min under normal incubator conditions, then trypsinized and fixed with 70% ethanol overnight. After fixation, cell pellets were collected, resuspended in 200&#x02009;&#x003bc;L 4&#x02009;M HCl, and incubated at room temperature for 20&#x02009;min, followed by neutralization with Borax. The cell pellets were washed twice with 1% BSA in PBS before incubation with the BrdU primary antibody (B2531; Sigma; clone BU-33) at room temperature for 30&#x02009;min in the dark. After three washes, the pellets were incubated with goat anti-mouse IgG Alexa Fluor 488 secondary antibody (ab150113; Abcam) at room temperature in the dark for 1&#x02009;h. Cell pellets were then washed three times with 1&#x02009;mL 0.1% Triton X-100 and 1% BSA in PBS before incubation with RNase A and propidium iodide (PI) at a final concentration of 5&#x02009;&#x003bc;g/mL PI for 15&#x02013;30&#x02009;min at room temperature in the dark. Samples were analyzed using a BD LSR Fortessa flow cytometer, and the data were analyzed with FlowJo software (BD Biosciences) with the Cell Cycle model.</p></sec><sec id="Sec30"><title>siRNA knockdown and plasmid transfection</title><p id="Par57">AllStars negative control siRNA from Qiagen (1027281) was used as control siRNA in knockdown experiments. <italic>IGF2BP1-3</italic>, <italic>TP53</italic>, <italic>EXOSC2</italic>, and <italic>METTL1</italic> siRNAs were ordered from Dharmacon as pre-desgined. Transfection was achieved by using Lipofectamine RNAiMAX (Invitrogen) for siRNA, and Lipofectamine 2000 (Invitrogen) for single type of plasmid or Lipofectamine LTX Plus (Invitrogen) for co-transfection of two or multiple types of plasmids (tethering assay) following the manufacturer&#x02019;s protocols.</p></sec><sec id="Sec31"><title>PAR-CLIP</title><p id="Par58">We followed the previously reported protocol. Eight 15&#x02009;cm plates of HepG2 cells were seeded for each replicate and grown to 80% confluency before the addition of 4&#x02009;&#x000b5;L 1&#x02009;M 4SU to each plate. After a 14&#x02009;h incubation, the media was aspirated; the cells were washed once with 5&#x02009;ml ice-cold PBS for each plate and crosslinked by 0.15&#x02009;J&#x02009;cm<sup>&#x02212;2</sup> 365&#x02009;nm UV light twice when on ice. The crosslinked cells were collected with cell lifters. 3 volumes of the lysis buffer (50&#x02009;mM HEPES, pH 7.5; 150&#x02009;mM KCl; 2&#x02009;mM EDTA; 0.5% (v/v) NP-40, with 1:100 protease inhibitor (Roche) and 40&#x02009;U&#x02009;ml<sup>&#x02212;1</sup> RNasin&#x000ae; Ribonuclease Inhibitors (Promega) added freshly) was added to the cell pellet and incubated on ice for 10&#x02009;min with periodic perturbation. The cell lysate was then centrifuged at 15,000&#x02009;g for 15&#x02009;min and the clear supernatant was collected. RNase T1 (1000&#x02009;U&#x02009;&#x000b5;L<sup>&#x02212;1</sup>, Thermo Fisher Scientific) was added to the clear lysate to a final concentration of 0.1&#x02009;U&#x02009;&#x000b5;L<sup>&#x02212;1</sup> and an incubation at room temperature was performed for 15&#x02009;min. The reaction was then quenched on ice. After 5&#x02009;min, antibodies were added to each sample (5&#x02009;&#x000b5;g or according to the manufacturer&#x02019;s protocols). The antibody and the lysate were incubated at 4&#x02009;&#x000b0;C for 2&#x02009;h under periodic rotation. Protein A beads or protein G beads (Thermo Fisher Scientific) were washed (50&#x02009;&#x000b5;L for each sample, or adjusted to the antibodies amount) with IP wash buffer (50&#x02009;mM HEPES, pH 7.5, 300&#x02009;mM KCl, 0.05% (v/v) NP-40, with 1:100 protease inhibitor (Roche) and 40 U ml<sup>&#x02212;1</sup> RNasin&#x000ae; Ribonuclease Inhibitors (Promega) added freshly) for 2&#x02009;times. The beads were resuspended in 50&#x02009;&#x000b5;L lysis buffer for each sample and added to the antibody-lysate mixture subsequently. Another 2-h incubation at 4&#x02009;&#x000b0;C was performed with low-speed rotation.</p><p id="Par59">After the incubation, the beads were washed three times with IP wash buffer (50&#x02009;mM HEPES, pH 7.5, 300&#x02009;mM KCl, 0.05% (v/v) NP-40, with 1:100 protease inhibitor (Roche) added freshly) and then resuspended with 200&#x02009;&#x000b5;L IP wash buffer per sample. The beads were treated with a second round of RNase T1 digestion under a final concentration of 10&#x02009;U &#x000b5;L<sup>&#x02212;1</sup> for 15&#x02009;min at room temperature. The reaction was then quenched with the addition of 10&#x02009;&#x000b5;L SUPERase-In followed by a 5-min incubation on ice. The beads were washed three times with high-salt wash buffer (50&#x02009;mM HEPES, pH 7.5, 500&#x02009;mM KCl, 0.05% (v/v) NP-40, with 1:100 protease inhibitor (Roche) added freshly) and twice with 1X PNK buffer (NEB) afterward. The beads were resuspended with 200&#x02009;&#x000b5;L of 1X PNK buffer (NEB) and underwent T4 PNK (Thermo Fisher Scientific) end repair with standard procedures as previously mentioned under 37&#x02009;&#x000b0;C. After the incubation, the beads were washed once with 1X PNK buffer followed by proteinase K digestion as described before. The RNA was recovered with RNA Clean &#x00026; Concentrator (Zymo Research) before library construction by NEBNext Small RNA Library Prep Set for Illumina (NEB). All libraries were sequenced on Illumina Nova Seq with single-end 100&#x02009;bp read length.</p></sec><sec id="Sec32"><title>ART-seq (active mRNA translation sequencing)</title><p id="Par60">Two days after transient knockdown of <italic>IGF2BP3</italic> in HepG2 cell in six-well plate, cycloheximide was added with the final concentration of 100&#x02009;&#x003bc;g/mL. The HepG2 cell was incubated at 37&#x02009;&#x000b0;C for 4&#x02009;min. The cells were washed twice with 0.5&#x02009;mL DPBS with 100&#x02009;&#x003bc;g/mL cycloheximide before added 0.4&#x02009;mL lysis buffer (20&#x02009;mM Tris-HCl pH 7.5, 100&#x02009;mM KCl, 5&#x02009;mM MgCl2, 0.5% NP-40, 1&#x02009;mM DTT, 0.1&#x02009;mg/mL cycloheximide, 0.1&#x02009;U/&#x000b5;L Invitrogen Turbo DNase). The cells were scraped and collected into 1.5&#x02009;mL tubes, and then incubated on ice with periodic inversions for 10&#x02009;min. The lysate was clarified by centrifugation for 10&#x02009;min at 20,000&#x02009;x&#x02009;g at 4&#x02009;&#x000b0;C. 0.3&#x02009;mL supernatant was transferred to a fresh tube. 300 U of RNAse I was added, and the lysate was incubated at room temperature for 45&#x02009;min. Afterwards, 15&#x02009;&#x003bc;L Invitrogen SUPERase&#x000b7;In&#x02122; RNase Inhibitor (20 U/&#x003bc;L) to stop this reaction. The 0.3&#x02009;mL of lysate was transferred to a prewashed MicroSpin S-400 column (Sigma: Microspin&#x02122; S-400 HR). The column was centrifuged at 600&#x02009;x&#x02009;g for 2&#x02009;min to collect flow-through. Zymo RNA Clean &#x00026; Concentrator Kit was used to purify RNA. The 28&#x02013;30 nt RPFs (ribosome-protected fragments) were excised from 10% TBU gel and recovered by ZR small-RNA&#x02122; PAGE Recovery Kit. The rRNA depletion was performed and the RPFs were end-repaired to have a 5&#x02019;-phosphate and 3&#x02019;-OH by T4 PNK treatment. The library was prepared with NEB small RNA library preparation kit.</p></sec><sec id="Sec33"><title>RNA-seq analysis</title><p id="Par61">Raw reads were trimmed with Trimmomatic-0.39<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>, then aligned to human genome and transcriptome (hg38) using HISAT (version 2.1.0)<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> with &#x02018;-rna-strandness RF&#x02019; parameters. Annotation files (version v29, 2018-08-30, in gtf format) were downloaded from GENCODE database (<ext-link ext-link-type="uri" xlink:href="https://www.gencodegenes.org/">https://www.gencodegenes.org/</ext-link>).</p></sec><sec id="Sec34"><title>MeRIP-seq analysis</title><p id="Par62">Mapped reads were separated by strands with samtools (version 1.9)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> and m<sup>6</sup>A peaks on each strand were called using MACS (version 2)<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> with parameter &#x02018;-nomodel, &#x02013;keep-dup 5, -g 1.3e8 and -extsize 150&#x02019; for m<sup>6</sup>A MeRIP-seq, and &#x02018;-nomodel, &#x02013;keep-dup 5, -g 1.3e8 and -extsize 75&#x02019; for m<sup>7</sup>G MeRIP-seq separately. Significant peaks with <italic>q</italic>&#x02009;&#x0003c;&#x02009;0.01 identified by MACS2 were considered. Peaks identified in at least three biological replicates were merged using bedtools (v.2.26.0)<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> and were used in the following analysis.</p></sec><sec id="Sec35"><title>Half lifetime total RNA-seq analysis</title><p id="Par63">Mapped reads on each GENCODE annotated gene were counted using HTSeq<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> and then normalized to counts per million (CPM) using edgeR<sup><xref ref-type="bibr" rid="CR73">73</xref></sup> packages in R. CPM was converted to attomole by linear fitting of the RNA ERCC spike-in. Half lifetime of RNA was estimated using formula listed in previously published paper<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Specifically, as actinomycin D treatment results in transcription stalling, the change of RNA concentration at a given time (dC/dt) is proportional to the constant of RNA decay (<italic>K</italic><sub><italic>decay</italic></sub>) and the RNA concentration (<italic>C</italic>), leading to the following equation:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dC}}{{dt}}=-\!{K}_{{decay}}C$$\end{document}</tex-math><mml:math id="M2"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.3em"/><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mi>C</mml:mi></mml:math><graphic xlink:href="41467_2024_51634_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par64">Thus, the RNA degradation rate <italic>K</italic><sub>decay</sub> was estimated by:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\mathrm{ln}}}\left(\frac{C}{{C}_{0}}\right)=-\!{K}_{{decay}}t$$\end{document}</tex-math><mml:math id="M4"><mml:mi mathvariant="normal">ln</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mfrac><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.3em"/><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mi>t</mml:mi></mml:math><graphic xlink:href="41467_2024_51634_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par65">To calculate the RNA half-life (<italic>t</italic><sub>1/2</sub>), when 50% of the RNA is decayed (that is, <inline-formula id="IEq1"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{C}{{C}_{0}}=\frac{1}{2}$$\end{document}</tex-math><mml:math id="M6"><mml:mfrac><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="41467_2024_51634_Article_IEq1.gif"/></alternatives></inline-formula>), the equation was:<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\mathrm{ln}}}\left(\frac{1}{2}\right)=-\!{K}_{{decay}}{t}_{\frac{1}{2}}$$\end{document}</tex-math><mml:math id="M8"><mml:mi mathvariant="normal">ln</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.3em"/><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msub></mml:math><graphic xlink:href="41467_2024_51634_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par66">From where:<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${t}_{\frac{1}{2}}=\frac{{ln}2}{{K}_{{decay}}}$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="41467_2024_51634_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula></p><p id="Par67">The final half-life was calculated by using the average values of 0&#x02009;h, 3&#x02009;h and 6&#x02009;h.</p></sec><sec id="Sec36"><title>ART-seq analysis</title><p id="Par68">Raw reads were trimmed using Cutadapt<sup><xref ref-type="bibr" rid="CR74">74</xref></sup> to remove low-quality bases and adapters. The trimmed reads were then aligned to the human genome (hg38) using STAR<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. Reads for each gene were counted using featureCounts<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. Translation efficiency (TE) was calculated as the ratio of ribosome-protected fragments (RPFs) to RNA abundance, as determined by ART-seq and RNA-seq and identified using DESeq2<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>.</p></sec><sec id="Sec37"><title>PAR-CLIP analysis</title><p id="Par69">Low quality reads were filtered using &#x02018;fastq_quality_filter&#x02019;, and adapter were clipped using &#x02018;fastx_clipper&#x02019;, then adapter-free were collapsed to remove PCR duplicates by using &#x02018;fastx_collapser&#x02019; and finally reads longer than 15&#x02009;nt were retained for further analysis (<ext-link ext-link-type="uri" xlink:href="http://hannonlab.cshl.edu/fastx_toolkit/">http://hannonlab.cshl.edu/fastx_toolkit/</ext-link>). Preprocessed reads were mapped using bowtie with &#x02018;-v 3 -m 10 &#x02013;best &#x02013;strata&#x02019; parameters. Peaks were called using PARalyzer<sup><xref ref-type="bibr" rid="CR78">78</xref></sup> software.</p></sec><sec id="Sec38"><title>Reporting summary</title><p id="Par70">Further information on research design is available in the&#x000a0;<xref rid="MOESM6" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec39" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2024_51634_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2024_51634_MOESM2_ESM.pdf"><caption><p>Peer Review File</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2024_51634_MOESM3_ESM.docx"><caption><p>Description of Additional Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41467_2024_51634_MOESM4_ESM.xlsx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41467_2024_51634_MOESM5_ESM.xlsx"><caption><p>Supplementary Data 2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41467_2024_51634_MOESM6_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p></sec><sec id="Sec40" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41467_2024_51634_MOESM7_ESM.xlsx"><caption><p>Source Data</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Chang Liu, Xiaoyang Dou, Yutao Zhao.</p></fn><fn><p><bold>Change history</bold></p><p>2/27/2025</p><p id="Par1">This article was originally published under a CC BY-NC-ND 4.0 license, but has now been made available under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. license. The PDF and HTML versions of the paper have been modified accordingly.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41467-024-51634-w.</p></sec><ack><title>Acknowledgements</title><p>This work was supported by R01 HL155909 (C.H.) and RM1 HG008935 (C.H.). The Mass Spectrometry Facility of the University of Chicago is funded by the National Science Foundation (CHE-1048528). C.H. is an investigator of the Howard Hughes Medical Institute. We thank Dr. Jianjun Chen (City of Hope) for gifting plasmids for IGF2BP family proteins with KH domain and RRM domain modified. We thank Dr. Pieter W. Faber and Genomics Facility of the University of Chicago for their generous help with high-throughput sequencing. This article is subject to HHMI&#x02019;s Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately upon publication.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>C.L. and C.H. conceived the project. C.L. and C.H. planned the experiments. C.L. designed and executed most experiments, analyzed the data, and produced figures. X.D. analyzed high throughput data and performed bioinformatic analyses. Y.Z. executed experiments, analyzed the data, and produced figures. L.Z., L.-S.Z., Q.D., J. L., T.W., and Y.X. contributed to experiments including cell proliferation, cell cycle, probe synthesis and data analysis. C.L. and C.H. wrote the manuscript. All authors contributed to the discussion of the results.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par71"><italic>Nature Communications</italic> thanks Yoon Ki Kim, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. A peer review file is available.</p></sec></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting the findings of this study are available from the corresponding authors upon request. m<sup>7</sup>G-MeRIP-seq in WT HepG2 cells, knockdown control cells, and METTL1 stable knockdown HepG2 cells, and m<sup>7</sup>G-seq in HepG2 cells were downloaded and re-analyzed in this study (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112276">GSE112276</ext-link>). The sequencing data produced in this study have been deposited in Gene Expression Ominibus (GEO) repository under the accession number <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE241222">GSE241222</ext-link>. The mass spectrometry proteomics data generated in this study have been deposited to the ProteomeXchange Consortium via the PRIDE<sup><xref ref-type="bibr" rid="CR79">79</xref></sup> partner repository with the dataset identifier PXD049390 and 10.6019/ <ext-link ext-link-type="uri" xlink:href="https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD049390">PXD049390</ext-link>. The list of top proteins enriched by m<sup>7</sup>G probes based on the proteomics data are provided in Supplementary Data&#x000a0;<xref rid="MOESM4" ref-type="media">1</xref>. The primers for dCas13b construction, guide RNA target sequences, and qPCR primers used in this study are summarized in Supplementary Data&#x000a0;<xref rid="MOESM5" ref-type="media">2</xref>.&#x000a0;<xref ref-type="sec" rid="Sec39">Source data</xref> are provided with this paper.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par72">C.H. is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and Ellis Bio, Inc., a scientific cofounder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics&#x000a0;and Element Biosciences. The remaining authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Boccaletto</surname><given-names>P</given-names></name><etal/></person-group><article-title>MODOMICS: a database of RNA modification pathways. 2017 update</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D303</fpage><lpage>D307</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1030</pub-id><pub-id pub-id-type="pmid">29106616</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Boccaletto, P. et al. MODOMICS: a database of RNA modification pathways. 2017 update. <italic>Nucleic Acids Res.</italic><bold>46</bold>, D303&#x02013;D307 (2018).<pub-id pub-id-type="pmid">29106616</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Desrosiers</surname><given-names>R</given-names></name><name><surname>Friderici</surname><given-names>K</given-names></name><name><surname>Rottman</surname><given-names>F</given-names></name></person-group><article-title>Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1974</year><volume>71</volume><fpage>3971</fpage><lpage>3975</lpage><pub-id pub-id-type="doi">10.1073/pnas.71.10.3971</pub-id><pub-id pub-id-type="pmid">4372599</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Desrosiers, R., Friderici, K. &#x00026; Rottman, F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. <italic>Proc. Natl Acad. Sci. USA</italic><bold>71</bold>, 3971&#x02013;3975 (1974).<pub-id pub-id-type="pmid">4372599</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>RP</given-names></name><name><surname>Kelley</surname><given-names>DE</given-names></name></person-group><article-title>Existence of methylated messenger RNA in mouse L cells</article-title><source>Cell</source><year>1974</year><volume>1</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(74)90153-6</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Perry, R. P. &#x00026; Kelley, D. E. Existence of methylated messenger RNA in mouse L cells. <italic>Cell</italic><bold>1</bold>, 37&#x02013;42 (1974).</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>N (6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>580</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1126/science.aay6018</pub-id><pub-id pub-id-type="pmid">31949099</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Liu, J. et al. N (6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. <italic>Science</italic><bold>367</bold>, 580&#x02013;586 (2020).<pub-id pub-id-type="pmid">31949099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Geula</surname><given-names>S</given-names></name><etal/></person-group><article-title>Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>1002</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1126/science.1261417</pub-id><pub-id pub-id-type="pmid">25569111</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Geula, S. et al. Stem cells. m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. <italic>Science</italic><bold>347</bold>, 1002&#x02013;1006 (2015).<pub-id pub-id-type="pmid">25569111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Exon architecture controls mRNA m(6)A suppression and gene expression</article-title><source>Science</source><year>2023</year><volume>379</volume><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1126/science.abj9090</pub-id><pub-id pub-id-type="pmid">36705538</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">He, P. C. et al. Exon architecture controls mRNA m(6)A suppression and gene expression. <italic>Science</italic><bold>379</bold>, 677&#x02013;682 (2023).<pub-id pub-id-type="pmid">36705538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><etal/></person-group><article-title>METTL3 regulates heterochromatin in mouse embryonic stem cells</article-title><source>Nature</source><year>2021</year><volume>591</volume><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03210-1</pub-id><pub-id pub-id-type="pmid">33505026</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Xu, W. et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. <italic>Nature</italic><bold>591</bold>, 317&#x02013;321 (2021).<pub-id pub-id-type="pmid">33505026</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>G</given-names></name><etal/></person-group><article-title>ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility</article-title><source>Mol. Cell</source><year>2013</year><volume>49</volume><fpage>18</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.10.015</pub-id><pub-id pub-id-type="pmid">23177736</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. <italic>Mol. Cell</italic><bold>49</bold>, 18&#x02013;29 (2013).<pub-id pub-id-type="pmid">23177736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis</article-title><source>Cell Res.</source><year>2014</year><volume>24</volume><fpage>1403</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1038/cr.2014.151</pub-id><pub-id pub-id-type="pmid">25412662</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zhao, X. et al. FTO-dependent demethylation of N6-methyladenosine regulates mRNA splicing and is required for adipogenesis. <italic>Cell Res.</italic><bold>24</bold>, 1403&#x02013;1419 (2014).<pub-id pub-id-type="pmid">25412662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Wei, J. et al. FTO mediates LINE1 m(6)A demethylation and chromatin regulation in mESCs and mouse development. <italic>Science</italic><bold>376</bold>, 968&#x02013;973 (2022).</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>N6-methyladenosine-dependent regulation of messenger RNA stability</article-title><source>Nature</source><year>2014</year><volume>505</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nature12730</pub-id><pub-id pub-id-type="pmid">24284625</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA stability. <italic>Nature</italic><bold>505</bold>, 117&#x02013;120 (2014).<pub-id pub-id-type="pmid">24284625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>N(6)-methyladenosine modulates messenger RNA translation efficiency</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>1388</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.014</pub-id><pub-id pub-id-type="pmid">26046440</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wang, X. et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. <italic>Cell</italic><bold>161</bold>, 1388&#x02013;1399 (2015).<pub-id pub-id-type="pmid">26046440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><fpage>127</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.11.017</pub-id><pub-id pub-id-type="pmid">28017614</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Li, Z. et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. <italic>Cancer Cell</italic><bold>31</bold>, 127&#x02013;141 (2017).<pub-id pub-id-type="pmid">28017614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>Q</given-names></name><etal/></person-group><article-title>m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells</article-title><source>Cell Rep</source><year>2017</year><volume>18</volume><fpage>2622</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.059</pub-id><pub-id pub-id-type="pmid">28297667</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cui, Q. et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. <italic>Cell Rep</italic><bold>18</bold>, 2622&#x02013;2634 (2017).<pub-id pub-id-type="pmid">28297667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader</article-title><source>Cell Death Differ</source><year>2020</year><volume>27</volume><fpage>1782</fpage><lpage>1794</lpage><pub-id pub-id-type="doi">10.1038/s41418-019-0461-z</pub-id><pub-id pub-id-type="pmid">31804607</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Hu, X. et al. IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. <italic>Cell Death Differ</italic><bold>27</bold>, 1782&#x02013;1794 (2020).<pub-id pub-id-type="pmid">31804607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Konarska</surname><given-names>MM</given-names></name><name><surname>Padgett</surname><given-names>RA</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group><article-title>Recognition of cap structure in splicing in vitro of mRNA precursors</article-title><source>Cell</source><year>1984</year><volume>38</volume><fpage>731</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(84)90268-X</pub-id><pub-id pub-id-type="pmid">6567484</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Konarska, M. M., Padgett, R. A. &#x00026; Sharp, P. A. Recognition of cap structure in splicing in vitro of mRNA precursors. <italic>Cell</italic><bold>38</bold>, 731&#x02013;736 (1984).<pub-id pub-id-type="pmid">6567484</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>DR</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Colman</surname><given-names>A</given-names></name></person-group><article-title>The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes</article-title><source>Nucleic Acids Res.</source><year>1985</year><volume>13</volume><fpage>7375</fpage><lpage>7394</lpage><pub-id pub-id-type="doi">10.1093/nar/13.20.7375</pub-id><pub-id pub-id-type="pmid">3932972</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Drummond, D. R., Armstrong, J. &#x00026; Colman, A. The effect of capping and polyadenylation on the stability, movement and translation of synthetic messenger RNAs in Xenopus oocytes. <italic>Nucleic Acids Res.</italic><bold>13</bold>, 7375&#x02013;7394 (1985).<pub-id pub-id-type="pmid">3932972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Izaurralde</surname><given-names>E</given-names></name></person-group><article-title>The role of the cap structure in RNA processing and nuclear export</article-title><source>Eur. J. Biochem.</source><year>1997</year><volume>247</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1997.00461.x</pub-id><pub-id pub-id-type="pmid">9266685</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lewis, J. D. &#x00026; Izaurralde, E. The role of the cap structure in RNA processing and nuclear export. <italic>Eur. J. Biochem.</italic><bold>247</bold>, 461&#x02013;469 (1997).<pub-id pub-id-type="pmid">9266685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>MP</given-names></name><name><surname>Phizicky</surname><given-names>EM</given-names></name></person-group><article-title>Two-subunit enzymes involved in eukaryotic post-transcriptional tRNA modification</article-title><source>RNA Biol.</source><year>2014</year><volume>11</volume><fpage>1608</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1080/15476286.2015.1008360</pub-id><pub-id pub-id-type="pmid">25625329</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Guy, M. P. &#x00026; Phizicky, E. M. Two-subunit enzymes involved in eukaryotic post-transcriptional tRNA modification. <italic>RNA Biol.</italic><bold>11</bold>, 1608&#x02013;1618 (2014).<pub-id pub-id-type="pmid">25625329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Tuning the ribosome: the influence of rRNA modification on eukaryotic ribosome biogenesis and function</article-title><source>RNA Biol.</source><year>2017</year><volume>14</volume><fpage>1138</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1080/15476286.2016.1259781</pub-id><pub-id pub-id-type="pmid">27911188</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Sloan, K. E. et al. Tuning the ribosome: the influence of rRNA modification on eukaryotic ribosome biogenesis and function. <italic>RNA Biol.</italic><bold>14</bold>, 1138&#x02013;1152 (2017).<pub-id pub-id-type="pmid">27911188</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Transcriptome-wide mapping of internal N(7)-methylguanosine methylome in mammalian mRNA</article-title><source>Mol. Cell</source><year>2019</year><volume>74</volume><fpage>1304</fpage><lpage>1316.e1308</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.03.036</pub-id><pub-id pub-id-type="pmid">31031084</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhang, L. S. et al. Transcriptome-wide mapping of internal N(7)-methylguanosine methylome in mammalian mRNA. <italic>Mol. Cell</italic><bold>74</bold>, 1304&#x02013;1316.e1308 (2019).<pub-id pub-id-type="pmid">31031084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Existence of internal N7-methylguanosine modification in mRNA determined by differential enzyme treatment coupled with mass spectrometry analysis</article-title><source>ACS Chem Biol.</source><year>2018</year><volume>13</volume><fpage>3243</fpage><lpage>3250</lpage><pub-id pub-id-type="doi">10.1021/acschembio.7b00906</pub-id><pub-id pub-id-type="pmid">29313662</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chu, J. M. et al. Existence of internal N7-methylguanosine modification in mRNA determined by differential enzyme treatment coupled with mass spectrometry analysis. <italic>ACS Chem Biol.</italic><bold>13</bold>, 3243&#x02013;3250 (2018).<pub-id pub-id-type="pmid">29313662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Enroth</surname><given-names>C</given-names></name><etal/></person-group><article-title>Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>e126</fpage><pub-id pub-id-type="doi">10.1093/nar/gkz736</pub-id><pub-id pub-id-type="pmid">31504776</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Enroth, C. et al. Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing. <italic>Nucleic Acids Res.</italic><bold>47</bold>, e126 (2019).<pub-id pub-id-type="pmid">31504776</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Malbec</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dynamic methylome of internal mRNA N(7)-methylguanosine and its regulatory role in translation</article-title><source>Cell Res.</source><year>2019</year><volume>29</volume><fpage>927</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1038/s41422-019-0230-z</pub-id><pub-id pub-id-type="pmid">31520064</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Malbec, L. et al. Dynamic methylome of internal mRNA N(7)-methylguanosine and its regulatory role in translation. <italic>Cell Res.</italic><bold>29</bold>, 927&#x02013;941 (2019).<pub-id pub-id-type="pmid">31520064</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A comprehensive analysis of METTL1 to immunity and stemness in pan-cancer</article-title><source>Front Immunol.</source><year>2022</year><volume>13</volume><fpage>795240</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.795240</pub-id><pub-id pub-id-type="pmid">35432338</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gao, Z. et al. A comprehensive analysis of METTL1 to immunity and stemness in pan-cancer. <italic>Front Immunol.</italic><bold>13</bold>, 795240 (2022).<pub-id pub-id-type="pmid">35432338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Campeanu</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>14784</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-94019-5</pub-id><pub-id pub-id-type="pmid">34285249</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Campeanu, I. J. et al. Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer. <italic>Sci. Rep.</italic><bold>11</bold>, 14784 (2021).<pub-id pub-id-type="pmid">34285249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Orellana</surname><given-names>EA</given-names></name><etal/></person-group><article-title>METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation</article-title><source>Mol. Cell</source><year>2021</year><volume>81</volume><fpage>3323</fpage><lpage>3338.e3314</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2021.06.031</pub-id><pub-id pub-id-type="pmid">34352207</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Orellana, E. A. et al. METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation. <italic>Mol. Cell</italic><bold>81</bold>, 3323&#x02013;3338.e3314 (2021).<pub-id pub-id-type="pmid">34352207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>METTL1 promotes neuroblastoma development through m(7)G tRNA modification and selective oncogenic gene translation</article-title><source>Biomark Res.</source><year>2022</year><volume>10</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.1186/s40364-022-00414-z</pub-id><pub-id pub-id-type="pmid">36071474</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Huang, Y. et al. METTL1 promotes neuroblastoma development through m(7)G tRNA modification and selective oncogenic gene translation. <italic>Biomark Res.</italic><bold>10</bold>, 68 (2022).<pub-id pub-id-type="pmid">36071474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>QKI shuttles internal m(7)G-modified transcripts into stress granules and modulates mRNA metabolism</article-title><source>Cell</source><year>2023</year><volume>186</volume><fpage>3208</fpage><lpage>3226.e3227</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.05.047</pub-id><pub-id pub-id-type="pmid">37379838</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhao, Z. et al. QKI shuttles internal m(7)G-modified transcripts into stress granules and modulates mRNA metabolism. <italic>Cell</italic><bold>186</bold>, 3208&#x02013;3226.e3227 (2023).<pub-id pub-id-type="pmid">37379838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>METTL1-mediated m(7)G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development</article-title><source>Stem Cell Res. Ther.</source><year>2020</year><volume>11</volume><fpage>306</fpage><pub-id pub-id-type="doi">10.1186/s13287-020-01814-4</pub-id><pub-id pub-id-type="pmid">32698871</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Deng, Y., Zhou, Z., Ji, W., Lin, S. &#x00026; Wang, M. METTL1-mediated m(7)G methylation maintains pluripotency in human stem cells and limits mesoderm differentiation and vascular development. <italic>Stem Cell Res. Ther.</italic><bold>11</bold>, 306 (2020).<pub-id pub-id-type="pmid">32698871</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mettl1/Wdr4-mediated m(7)G tRNA mMethylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation</article-title><source>Mol. Cell</source><year>2018</year><volume>71</volume><fpage>244</fpage><lpage>255.e245</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.001</pub-id><pub-id pub-id-type="pmid">29983320</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lin, S. et al. Mettl1/Wdr4-mediated m(7)G tRNA mMethylome is required for normal mRNA translation and embryonic stem cell self-renewal and differentiation. <italic>Mol. Cell</italic><bold>71</bold>, 244&#x02013;255.e245 (2018).<pub-id pub-id-type="pmid">29983320</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>QH</given-names></name><etal/></person-group><article-title>METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN</article-title><source>J. Mol. Med. (Berl)</source><year>2019</year><volume>97</volume><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1007/s00109-019-01830-9</pub-id><pub-id pub-id-type="pmid">31463732</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tian, Q. H. et al. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. <italic>J. Mol. Med. (Berl)</italic><bold>97</bold>, 1535&#x02013;1545 (2019).<pub-id pub-id-type="pmid">31463732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><article-title>Cancer. p53, guardian of the genome</article-title><source>Nature</source><year>1992</year><volume>358</volume><fpage>15</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/358015a0</pub-id><pub-id pub-id-type="pmid">1614522</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lane, D. P. Cancer. p53, guardian of the genome. <italic>Nature</italic><bold>358</bold>, 15&#x02013;16 (1992).<pub-id pub-id-type="pmid">1614522</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Zhang, Y. et al. The p53 pathway in glioblastoma. <italic>Cancers (Basel)</italic><bold>10</bold>, 297 (2018).</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Erwin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Analysis of the p53 gene and its expression in human glioblastoma cells</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">8306326</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Erwin, G. et al. Analysis of the p53 gene and its expression in human glioblastoma cells. <italic>Cancer Res</italic><bold>54</bold>, 649&#x02013;652 (1994).<pub-id pub-id-type="pmid">8306326</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>N</given-names></name><etal/></person-group><article-title>Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines</article-title><source>Brain Pathol.</source><year>1999</year><volume>9</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.1999.tb00536.x</pub-id><pub-id pub-id-type="pmid">10416987</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Ishii, N. et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. <italic>Brain Pathol.</italic><bold>9</bold>, 469&#x02013;479 (1999).<pub-id pub-id-type="pmid">10416987</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>A</given-names></name><etal/></person-group><article-title>p53-independent tumor suppression by cell-cycle arrest via CREB/ATF transcription factor OASIS</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112479</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112479</pub-id><pub-id pub-id-type="pmid">37178686</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Saito, A. et al. p53-independent tumor suppression by cell-cycle arrest via CREB/ATF transcription factor OASIS. <italic>Cell Rep.</italic><bold>42</bold>, 112479 (2023).<pub-id pub-id-type="pmid">37178686</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>de Andrade</surname><given-names>KC</given-names></name><etal/></person-group><article-title>The TP53 Database: transition from the international agency for research on cancer to the US national cancer institute</article-title><source>Cell Death Differ.</source><year>2022</year><volume>29</volume><fpage>1071</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-00976-3</pub-id><pub-id pub-id-type="pmid">35352025</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">de Andrade, K. C. et al. The TP53 Database: transition from the international agency for research on cancer to the US national cancer institute. <italic>Cell Death Differ.</italic><bold>29</bold>, 1071&#x02013;1073 (2022).<pub-id pub-id-type="pmid">35352025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation</article-title><source>Mol Cancer Res.</source><year>2010</year><volume>8</volume><fpage>701</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-09-0442</pub-id><pub-id pub-id-type="pmid">20407015</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Jordan, J. J. et al. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. <italic>Mol Cancer Res.</italic><bold>8</bold>, 701&#x02013;716 (2010).<pub-id pub-id-type="pmid">20407015</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>D</given-names></name><name><surname>Inga</surname><given-names>A</given-names></name><name><surname>Resnick</surname><given-names>MA</given-names></name></person-group><article-title>Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>1500</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909129107</pub-id><pub-id pub-id-type="pmid">20080630</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Menendez, D., Inga, A. &#x00026; Resnick, M. A. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. <italic>Proc. Natl Acad. Sci. USA</italic><bold>107</bold>, 1500&#x02013;1505 (2010).<pub-id pub-id-type="pmid">20080630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonin-Laurent</surname><given-names>N</given-names></name><etal/></person-group><article-title>Specific TP53 mutation pattern in radiation-induced sarcomas</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>1266</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgi356</pub-id><pub-id pub-id-type="pmid">16492679</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Gonin-Laurent, N. et al. Specific TP53 mutation pattern in radiation-induced sarcomas. <italic>Carcinogenesis</italic><bold>27</bold>, 1266&#x02013;1272 (2006).<pub-id pub-id-type="pmid">16492679</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrote</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Oncogenic gain of function in glioblastoma is linked to mutant p53 amyloid oligomers</article-title><source>iScience</source><year>2020</year><volume>23</volume><fpage>100820</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.100820</pub-id><pub-id pub-id-type="pmid">31981923</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Pedrote, M. M. et al. Oncogenic gain of function in glioblastoma is linked to mutant p53 amyloid oligomers. <italic>iScience</italic><bold>23</bold>, 100820 (2020).<pub-id pub-id-type="pmid">31981923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?</article-title><source>Cell Mol. Life Sci.</source><year>2013</year><volume>70</volume><fpage>2657</fpage><lpage>2675</lpage><pub-id pub-id-type="doi">10.1007/s00018-012-1186-z</pub-id><pub-id pub-id-type="pmid">23069990</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Bell, J. L. et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? <italic>Cell Mol. Life Sci.</italic><bold>70</bold>, 2657&#x02013;2675 (2013).<pub-id pub-id-type="pmid">23069990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Lederer</surname><given-names>M</given-names></name><name><surname>Bley</surname><given-names>N</given-names></name><name><surname>Schleifer</surname><given-names>C</given-names></name><name><surname>Huttelmaier</surname><given-names>S</given-names></name></person-group><article-title>The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer</article-title><source>Semin. Cancer Biol.</source><year>2014</year><volume>29</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2014.07.006</pub-id><pub-id pub-id-type="pmid">25068994</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lederer, M., Bley, N., Schleifer, C. &#x00026; Huttelmaier, S. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. <italic>Semin. Cancer Biol.</italic><bold>29</bold>, 3&#x02013;12 (2014).<pub-id pub-id-type="pmid">25068994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Mu</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name></person-group><article-title>The roles of insulin-like growth factor 2 mRNA-binding protein 2 in cancer and cancer stem cells</article-title><source>Stem Cells Int.</source><year>2018</year><volume>2018</volume><fpage>4217259</fpage><pub-id pub-id-type="doi">10.1155/2018/4217259</pub-id><pub-id pub-id-type="pmid">29736175</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Cao, J., Mu, Q. &#x00026; Huang, H. The roles of insulin-like growth factor 2 mRNA-binding protein 2 in cancer and cancer stem cells. <italic>Stem Cells Int.</italic><bold>2018</bold>, 4217259 (2018).<pub-id pub-id-type="pmid">29736175</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation</article-title><source>Nat. Cell Biol.</source><year>2018</year><volume>20</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0045-z</pub-id><pub-id pub-id-type="pmid">29476152</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Huang, H. et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. <italic>Nat. Cell Biol.</italic><bold>20</bold>, 285&#x02013;295 (2018).<pub-id pub-id-type="pmid">29476152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><etal/></person-group><article-title>The structural basis for RNA selectivity by the IMP family of RNA-binding proteins</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>4440</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-12193-7</pub-id><pub-id pub-id-type="pmid">31570709</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Biswas, J. et al. The structural basis for RNA selectivity by the IMP family of RNA-binding proteins. <italic>Nat. Commun.</italic><bold>10</bold>, 4440 (2019).<pub-id pub-id-type="pmid">31570709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Spatial arrangement of an RNA zipcode identifies mRNAs under post-transcriptional control</article-title><source>Genes Dev.</source><year>2012</year><volume>26</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1101/gad.177428.111</pub-id><pub-id pub-id-type="pmid">22215810</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Patel, V. L. et al. Spatial arrangement of an RNA zipcode identifies mRNAs under post-transcriptional control. <italic>Genes Dev.</italic><bold>26</bold>, 43&#x02013;53 (2012).<pub-id pub-id-type="pmid">22215810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>T</given-names></name><etal/></person-group><article-title>Combinatorial recognition of clustered RNA elements by the multidomain RNA-binding protein IMP3</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2266</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09769-8</pub-id><pub-id pub-id-type="pmid">31118463</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Schneider, T. et al. Combinatorial recognition of clustered RNA elements by the multidomain RNA-binding protein IMP3. <italic>Nat. Commun.</italic><bold>10</bold>, 2266 (2019).<pub-id pub-id-type="pmid">31118463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>M</given-names></name><etal/></person-group><article-title>MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma</article-title><source>Cell Death Discov.</source><year>2022</year><volume>8</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1038/s41420-022-00844-6</pub-id><pub-id pub-id-type="pmid">35136045</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Du, M. et al. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. <italic>Cell Death Discov.</italic><bold>8</bold>, 53 (2022).<pub-id pub-id-type="pmid">35136045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Knockdown of m6A reader IGF2BP3 inhibited hypoxia-induced cell migration and angiogenesis by regulating hypoxia inducible factor-1alpha in stomach cancer</article-title><source>Front Oncol.</source><year>2021</year><volume>11</volume><fpage>711207</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.711207</pub-id><pub-id pub-id-type="pmid">34621671</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Jiang, L. et al. Knockdown of m6A reader IGF2BP3 inhibited hypoxia-induced cell migration and angiogenesis by regulating hypoxia inducible factor-1alpha in stomach cancer. <italic>Front Oncol.</italic><bold>11</bold>, 711207 (2021).<pub-id pub-id-type="pmid">34621671</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Tsuchiya, K. et al. m(6)A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer. <italic>Cancer Gene. Ther.</italic><bold>29</bold>, 1355&#x02013;1372 (2022).</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>5684</fpage><lpage>5694</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa269</pub-id><pub-id pub-id-type="pmid">32356894</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Li, J. et al. Targeted mRNA demethylation using an engineered dCas13b-ALKBH5 fusion protein. <italic>Nucleic Acids Res.</italic><bold>48</bold>, 5684&#x02013;5694 (2020).<pub-id pub-id-type="pmid">32356894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Dickinson</surname><given-names>BC</given-names></name></person-group><article-title>Targeted m(6)A reader proteins to study epitranscriptomic regulation of single RNAs</article-title><source>J. Am. Chem. Soc.</source><year>2018</year><volume>140</volume><fpage>11974</fpage><lpage>11981</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b05012</pub-id><pub-id pub-id-type="pmid">30183280</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Rauch, S., He, C. &#x00026; Dickinson, B. C. Targeted m(6)A reader proteins to study epitranscriptomic regulation of single RNAs. <italic>J. Am. Chem. Soc.</italic><bold>140</bold>, 11974&#x02013;11981 (2018).<pub-id pub-id-type="pmid">30183280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Miao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>DR</given-names></name></person-group><article-title>Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>1431</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0572-6</pub-id><pub-id pub-id-type="pmid">32601430</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Wilson, C., Chen, P. J., Miao, Z. &#x00026; Liu, D. R. Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase. <italic>Nat. Biotechnol.</italic><bold>38</bold>, 1431&#x02013;1440 (2020).<pub-id pub-id-type="pmid">32601430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Mizutani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><fpage>3495</fpage><lpage>3502</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.410</pub-id><pub-id pub-id-type="pmid">26522719</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Mizutani, R. et al. Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. <italic>Oncogene</italic><bold>35</bold>, 3495&#x02013;3502 (2016).<pub-id pub-id-type="pmid">26522719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Zinder</surname><given-names>JC</given-names></name><name><surname>Lima</surname><given-names>CD</given-names></name></person-group><article-title>Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors</article-title><source>Genes Dev.</source><year>2017</year><volume>31</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1101/gad.294769.116</pub-id><pub-id pub-id-type="pmid">28202538</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Zinder, J. C. &#x00026; Lima, C. D. Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors. <italic>Genes Dev.</italic><bold>31</bold>, 88&#x02013;100 (2017).<pub-id pub-id-type="pmid">28202538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Gerlach, P. et al. Distinct and evolutionary conserved structural features of the human nuclear exosome complex. <italic>Elife</italic><bold>7</bold>, e38686 (2018).</mixed-citation></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilchert</surname><given-names>C</given-names></name><name><surname>Wittmann</surname><given-names>S</given-names></name><name><surname>Vasiljeva</surname><given-names>L</given-names></name></person-group><article-title>The regulation and functions of the nuclear RNA exosome complex</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2016</year><volume>17</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/nrm.2015.15</pub-id><pub-id pub-id-type="pmid">26726035</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kilchert, C., Wittmann, S. &#x00026; Vasiljeva, L. The regulation and functions of the nuclear RNA exosome complex. <italic>Nat. Rev. Mol. Cell Biol.</italic><bold>17</bold>, 227&#x02013;239 (2016).<pub-id pub-id-type="pmid">26726035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>T</given-names></name><name><surname>Nakagawara</surname><given-names>A</given-names></name></person-group><article-title>Role of p53 in cell death and human cancers</article-title><source>Cancers (Basel)</source><year>2011</year><volume>3</volume><fpage>994</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.3390/cancers3010994</pub-id><pub-id pub-id-type="pmid">24212651</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Ozaki, T. &#x00026; Nakagawara, A. Role of p53 in cell death and human cancers. <italic>Cancers (Basel)</italic><bold>3</bold>, 994&#x02013;1013 (2011).<pub-id pub-id-type="pmid">24212651</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Engeland</surname><given-names>K</given-names></name></person-group><article-title>Cell cycle regulation: p53-p21-RB signaling</article-title><source>Cell Death Differ</source><year>2022</year><volume>29</volume><fpage>946</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-00988-z</pub-id><pub-id pub-id-type="pmid">35361964</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Engeland, K. Cell cycle regulation: p53-p21-RB signaling. <italic>Cell Death Differ</italic><bold>29</bold>, 946&#x02013;960 (2022).<pub-id pub-id-type="pmid">35361964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression</article-title><source>Cold Spring Harb. Perspect Med.</source><year>2016</year><volume>6</volume><fpage>a026104</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a026104</pub-id><pub-id pub-id-type="pmid">26931810</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Chen, J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. <italic>Cold Spring Harb. Perspect Med.</italic><bold>6</bold>, a026104 (2016).<pub-id pub-id-type="pmid">26931810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>N</given-names></name><etal/></person-group><article-title>The Mettl3 epitranscriptomic writer amplifies p53 stress responses</article-title><source>Mol. Cell</source><year>2022</year><volume>82</volume><fpage>2370</fpage><lpage>2384 e2310</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.04.010</pub-id><pub-id pub-id-type="pmid">35512709</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Raj, N. et al. The Mettl3 epitranscriptomic writer amplifies p53 stress responses. <italic>Mol. Cell</italic><bold>82</bold>, 2370&#x02013;2384 e2310 (2022).<pub-id pub-id-type="pmid">35512709</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>MM</given-names></name><name><surname>Gomez-Manzano</surname><given-names>C</given-names></name><name><surname>Bekele</surname><given-names>BN</given-names></name><name><surname>Yung</surname><given-names>WK</given-names></name><name><surname>Fueyo</surname><given-names>J</given-names></name></person-group><article-title>Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>11499</fpage><lpage>11504</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5312</pub-id><pub-id pub-id-type="pmid">18089777</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Alonso, M. M., Gomez-Manzano, C., Bekele, B. N., Yung, W. K. &#x00026; Fueyo, J. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. <italic>Cancer Res.</italic><bold>67</bold>, 11499&#x02013;11504 (2007).<pub-id pub-id-type="pmid">18089777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway</article-title><source>Oncol. Rep.</source><year>2012</year><volume>27</volume><fpage>2050</fpage><lpage>2056</lpage><pub-id pub-id-type="pmid">22426504</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Huang, H., Lin, H., Zhang, X. &#x00026; Li, J. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. <italic>Oncol. Rep.</italic><bold>27</bold>, 2050&#x02013;2056 (2012).<pub-id pub-id-type="pmid">22426504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name></person-group><article-title>Temozolomide resistance in glioblastoma multiforme</article-title><source>Genes Dis.</source><year>2016</year><volume>3</volume><fpage>198</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2016.04.007</pub-id><pub-id pub-id-type="pmid">30258889</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Lee, S. Y. Temozolomide resistance in glioblastoma multiforme. <italic>Genes Dis.</italic><bold>3</bold>, 198&#x02013;210 (2016).<pub-id pub-id-type="pmid">30258889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Liu</surname><given-names>YH</given-names></name><name><surname>You</surname><given-names>C</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name></person-group><article-title>Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase</article-title><source>Neurol. Sci.</source><year>2013</year><volume>34</volume><fpage>1421</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1007/s10072-012-1257-9</pub-id><pub-id pub-id-type="pmid">23224642</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Wang, X., Chen, J. X., Liu, Y. H., You, C. &#x00026; Mao, Q. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. <italic>Neurol. Sci.</italic><bold>34</bold>, 1421&#x02013;1428 (2013).<pub-id pub-id-type="pmid">23224642</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Bolger, A. M., Lohse, M. &#x00026; Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. <italic>Bioinformatics</italic><bold>30</bold>, 2114&#x02013;2120 (2014).<pub-id pub-id-type="pmid">24695404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Paggi</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>C</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype</article-title><source>Nat. Biotechnol.</source><year>2019</year><volume>37</volume><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0201-4</pub-id><pub-id pub-id-type="pmid">31375807</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Kim, D., Paggi, J. M., Park, C., Bennett, C. &#x00026; Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. <italic>Nat. Biotechnol.</italic><bold>37</bold>, 907&#x02013;915 (2019).<pub-id pub-id-type="pmid">31375807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><mixed-citation publication-type="other">Danecek, P. et al. Twelve years of SAMtools and BCFtools. <italic>Gigascience</italic><bold>10</bold>, giab008 (2021).</mixed-citation></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Model-based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biol.</source><year>2008</year><volume>9</volume><fpage>R137</fpage><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). <italic>Genome Biol.</italic><bold>9</bold>, R137 (2008).<pub-id pub-id-type="pmid">18798982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Pyl</surname><given-names>PT</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>HTSeq&#x02013;a python framework to work with high-throughput sequencing data</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu638</pub-id><pub-id pub-id-type="pmid">25260700</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Anders, S., Pyl, P. T. &#x00026; Huber, W. HTSeq&#x02013;a python framework to work with high-throughput sequencing data. <italic>Bioinformatics</italic><bold>31</bold>, 166&#x02013;169 (2015).<pub-id pub-id-type="pmid">25260700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Robinson, M. D., McCarthy, D. J. &#x00026; Smyth, G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. <italic>Bioinformatics</italic><bold>26</bold>, 139&#x02013;140 (2010).<pub-id pub-id-type="pmid">19910308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. <italic>BMBnet. J.</italic>10.14806/ej.17.1.200 (2011).</mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. <italic>Bioinformatics</italic><bold>29</bold>, 15&#x02013;21 (2013).<pub-id pub-id-type="pmid">23104886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Liao, Y., Smyth, G. K. &#x00026; Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. <italic>Bioinformatics</italic><bold>30</bold>, 923&#x02013;930 (2014).<pub-id pub-id-type="pmid">24227677</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Love, M. I., Huber, W. &#x00026; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <italic>Genome Biol.</italic><bold>15</bold>, 550 (2014).<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Corcoran</surname><given-names>DL</given-names></name><etal/></person-group><article-title>PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data</article-title><source>Genome Biol.</source><year>2011</year><volume>12</volume><fpage>R79</fpage><pub-id pub-id-type="doi">10.1186/gb-2011-12-8-r79</pub-id><pub-id pub-id-type="pmid">21851591</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Corcoran, D. L. et al. PARalyzer: definition of RNA binding sites from PAR-CLIP short-read sequence data. <italic>Genome Biol.</italic><bold>12</bold>, R79 (2011).<pub-id pub-id-type="pmid">21851591</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res.</source><year>2022</year><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id><pub-id pub-id-type="pmid">34723319</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. <italic>Nucleic Acids Res.</italic><bold>50</bold>, D543&#x02013;D552 (2022).<pub-id pub-id-type="pmid">34723319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyers</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1779</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1038/ng.3984</pub-id><pub-id pub-id-type="pmid">29083409</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. <italic>Nat. Genet.</italic><bold>49</bold>, 1779&#x02013;1784 (2017).<pub-id pub-id-type="pmid">29083409</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>